<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">68388</article-id><article-id pub-id-type="doi">10.7554/eLife.68388</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon hepatitis B vaccination</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-230337"><name><surname>Elias</surname><given-names>George</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8419-9544</contrib-id><email>igeorgeelias@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-76981"><name><surname>Meysman</surname><given-names>Pieter</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5903-633X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-104917"><name><surname>Bartholomeus</surname><given-names>Esther</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230338"><name><surname>De Neuter</surname><given-names>Nicolas</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6011-6457</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-104919"><name><surname>Keersmaekers</surname><given-names>Nina</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-104920"><name><surname>Suls</surname><given-names>Arvid</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230339"><name><surname>Jansens</surname><given-names>Hilde</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230340"><name><surname>Souquette</surname><given-names>Aisha</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230341"><name><surname>De Reu</surname><given-names>Hans</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-265053"><name><surname>Emonds</surname><given-names>Marie-Paule</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-104922"><name><surname>Smits</surname><given-names>Evelien</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230342"><name><surname>Lion</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-42849"><name><surname>Thomas</surname><given-names>Paul G</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-104925"><name><surname>Mortier</surname><given-names>Geert</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-104924"><name><surname>Van Damme</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-104923"><name><surname>Beutels</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-104927"><name><surname>Laukens</surname><given-names>Kris</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-230343"><name><surname>Van Tendeloo</surname><given-names>Viggo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-230344"><name><surname>Ogunjimi</surname><given-names>Benson</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0831-2063</contrib-id><email>benson.ogunjimi@uantwerpen.be</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Laboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute, University of Antwerp</institution><addr-line><named-content content-type="city">Antwerp</named-content></addr-line><country>Belgium</country></aff><aff id="aff2"><label>2</label><institution>Antwerp Unit for Data Analysis and Computation in Immunology and Sequencing, University of Antwerp</institution><addr-line><named-content content-type="city">Antwerp</named-content></addr-line><country>Belgium</country></aff><aff id="aff3"><label>3</label><institution>Adrem Data Lab, Department of Mathematics and Computer Science, University of Antwerp</institution><addr-line><named-content content-type="city">Antwerp</named-content></addr-line><country>Belgium</country></aff><aff id="aff4"><label>4</label><institution>Biomedical Informatics Research Network Antwerp, University of Antwerp</institution><addr-line><named-content content-type="city">Antwerp</named-content></addr-line><country>Belgium</country></aff><aff id="aff5"><label>5</label><institution>Department of Medical Genetics, University of Antwerp</institution><addr-line><named-content content-type="city">Antwerp</named-content></addr-line><country>Belgium</country></aff><aff id="aff6"><label>6</label><institution>Centre for Health Economics Research &amp; Modeling Infectious Diseases, Vaccine &amp; Infectious Disease Institute (VAXINFECTIO), University of Antwerp</institution><addr-line><named-content content-type="city">Antwerp</named-content></addr-line><country>Belgium</country></aff><aff id="aff7"><label>7</label><institution>Department of Clinical Microbiology, Antwerp University Hospital</institution><addr-line><named-content content-type="city">Antwerp</named-content></addr-line><country>Belgium</country></aff><aff id="aff8"><label>8</label><institution>Department of Immunology, St. Jude Children's Research Hospital</institution><addr-line><named-content content-type="city">Memphis</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital</institution><addr-line><named-content content-type="city">Antwerp</named-content></addr-line><country>Belgium</country></aff><aff id="aff10"><label>10</label><institution>Histocompatibility and Immunogenetic Laboratory, Rode Kruis-Vlaanderen</institution><addr-line><named-content content-type="city">Mechelen</named-content></addr-line><country>Belgium</country></aff><aff id="aff11"><label>11</label><institution>Centre for the Evaluation of Vaccination (CEV), Vaccine and Infectious Disease Institute, University of Antwerp</institution><addr-line><named-content content-type="city">Antwerp</named-content></addr-line><country>Belgium</country></aff><aff id="aff12"><label>12</label><institution>Antwerp Center for Translational Immunology and Virology (ACTIV), Vaccine and Infectious Disease Institute, University of Antwerp</institution><addr-line><named-content content-type="city">Antwerp</named-content></addr-line><country>Belgium</country></aff><aff id="aff13"><label>13</label><institution>Department of Paediatrics, Antwerp University Hospital</institution><addr-line><named-content content-type="city">Antwerp</named-content></addr-line><country>Belgium</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Nourmohammad</surname><given-names>Armita</given-names></name><role>Reviewing Editor</role><aff><institution>University of Washington</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Walczak</surname><given-names>Aleksandra M</given-names></name><role>Senior Editor</role><aff><institution>École Normale Supérieure</institution><country>France</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>Janssen Research and Development, Immunosciences WWDA, Johnson and Johnson, Beerse, Belgium</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>25</day><month>01</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e68388</elocation-id><history><date date-type="received" iso-8601-date="2021-03-14"><day>14</day><month>03</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-01-07"><day>07</day><month>01</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2020-08-25"><day>25</day><month>08</month><year>2020</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2020.08.22.262568"/></event></pub-history><permissions><copyright-statement>© 2022, Elias et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Elias et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-68388-v3.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-68388-figures-v3.pdf"/><abstract><p>Antigen recognition through the T cell receptor (TCR) αβ heterodimer is one of the primary determinants of the adaptive immune response. Vaccines activate naïve T cells with high specificity to expand and differentiate into memory T cells. However, antigen-specific memory CD4 T cells exist in unexposed antigen-naïve hosts. In this study, we use high-throughput sequencing of memory CD4 TCRβ repertoire and machine learning to show that individuals with preexisting vaccine-reactive memory CD4 T cell clonotypes elicited earlier and higher antibody titers and mounted a more robust CD4 T cell response to hepatitis B vaccine. In addition, integration of TCRβ sequence patterns into a hepatitis B epitope-specific annotation model can predict which individuals will have an early and more vigorous vaccine-elicited immunity. Thus, the presence of preexisting memory T cell clonotypes has a significant impact on immunity and can be used to predict immune responses to vaccination.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Immune cells called CD4 T cells help the body build immunity to infections caused by bacteria and viruses, or after vaccination. Receptor proteins on the outside of the cells recognize pathogens, foreign molecules called antigens, or vaccine antigens. Vaccine antigens are usually inactivated bacteria or viruses, or fragments of these pathogens. After recognizing an antigen, CD4 T cells develop into memory CD4 T cells ready to defend against future infections with the pathogen.</p><p>People who have never been exposed to a pathogen, or have never been vaccinated against it, may nevertheless have preexisting memory cells ready to defend against it. This happens because CD4 T cells can recognize multiple targets, which enables the immune system to be ready to defend against both new and familiar pathogens.</p><p>Elias, Meysman, Bartholomeus et al. wanted to find out whether having preexisting memory CD4 T cells confers an advantage for vaccine-induced immunity. Thirty-four people who were never exposed to hepatitis B or vaccinated against it participated in the study. These individuals provided blood samples before vaccination, with 2 doses of the hepatitis B vaccine, and at 3 time points afterward. Using next generation immune sequencing and machine learning techniques, Elias et al. analyzed the individuals’ memory CD4 T cells before and after vaccination.</p><p>The experiments showed that preexisting memory CD4 T cells may determine vaccination outcomes, and people with more preexisting memory cells develop quicker and stronger immunity after vaccination against hepatitis B. This information may help scientists to better understand how people develop immunity to pathogens. It may guide them develop better vaccines or predict who will develop immunity after vaccination.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>CD4 T cell</kwd><kwd>T cell receptor</kwd><kwd>TCR repertoire</kwd><kwd>vaccination</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007660</institution-id><institution>Universiteit Antwerpen</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Elias</surname><given-names>George</given-names></name><name><surname>Bartholomeus</surname><given-names>Esther</given-names></name><name><surname>De Neuter</surname><given-names>Nicolas</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Research Foundation Flanders</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Meysman</surname><given-names>Pieter</given-names></name><name><surname>Laukens</surname><given-names>Kris</given-names></name><name><surname>Ogunjimi</surname><given-names>Benson</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012524</institution-id><institution>American Lebanese Syrian Associated Charities</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Souquette</surname><given-names>Aisha</given-names></name><name><surname>Thomas</surname><given-names>Paul G</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Souquette</surname><given-names>Aisha</given-names></name><name><surname>Thomas</surname><given-names>Paul G</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>High-throughput sequencing of the memory T cell receptor repertoire and machine learning can predict robust antibody and CD4 T cell response to de novo hepatitis B vaccine.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Antigen recognition through the T cell receptor (TCR) is one of the key determinants of the adaptive immune response (<xref ref-type="bibr" rid="bib53">Rudolph et al., 2006</xref>). Antigen presentation via major histocompatibility complex (MHC) proteins, together with the right costimulatory and cytokine signals, are responsible for T cell activation (<xref ref-type="bibr" rid="bib11">Curtsinger and Mescher, 2010</xref>; <xref ref-type="bibr" rid="bib19">Esensten et al., 2016</xref>). The TCR αβ heterodimer binds the peptide-MHC (pMHC) complex and confers the specificity of a T cell to an epitope. A highly diverse TCR repertoire ensures that an effective T cell response can be mounted against pathogen-derived peptides (<xref ref-type="bibr" rid="bib62">Turner et al., 2009</xref>). High TCRαβ diversity is generated through V(D)J recombination at the complementary-determining region 3 (CDR3) of TCRα and TCRβ chains, accompanied with junctional deletions and insertions of nucleotides, further adding to the diversity (<xref ref-type="bibr" rid="bib33">Krangel, 2009</xref>).</p><p>Vaccines activate naïve T cells with high specificity to vaccine-derived peptides and induce T cell expansion and differentiation into effective and multifunctional T cells. This is followed by a contraction phase from which surviving cells constitute a long-lived memory T cell pool that allows for a quick and robust T cell response upon a second exposure to the pathogen (<xref ref-type="bibr" rid="bib20">Farber et al., 2014</xref>). However, previous studies have shown that a prior pathogen encounter is not a prerequisite for the formation of memory T cells and that CD4 T cells with a memory phenotype can be found in antigen-naïve individuals (<xref ref-type="bibr" rid="bib61">Su et al., 2013</xref>). The existence of memory-like CD4 T cells in naïve individuals (<xref ref-type="bibr" rid="bib58">Sewell, 2012</xref>) can be explained by molecular mimicry, as the encounter with environmentally derived peptides activates cross-reactive T cells due to the flexible nature of CD4 T cell recognition of the pMHC complex (<xref ref-type="bibr" rid="bib65">Wilson et al., 2004</xref>). Indeed, work that attempted to replicate the history of human pathogen exposure in mice has shown that sequential infections altered the immunological profile and remodeled the immune response to vaccination (<xref ref-type="bibr" rid="bib49">Reese et al., 2016</xref>). The existence of memory CD4 T cells specific to vaccine-derived peptides in unexposed individuals might confer an advantage in vaccine-induced immunity. In the present study, we used high-throughput sequencing to profile the memory CD4 TCRβ repertoire of healthy hepatitis B (HB)-naïve adults before and after administration of an HB vaccine to investigate the impact of preexisting memory CD4 T cells on the immune response to the vaccine. Based on anti-hepatitis B surface (anti-HBs) antibody titers over 365 days, vaccinees were grouped into early-, late-, and non-converters. Our data reveals that individuals with preexisting vaccine-specific CD4 T cell clonotypes in the memory CD4 compartment had earlier emergence of antibodies and mounted a more vigorous CD4 T cell response to the vaccine. Moreover, we identify a set of vaccine-specific TCRβ sequence patterns which can be used to predict TCR specificity and in turn, which individuals will have an early and more vigorous response to HB vaccine.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Vaccinee cohort can be classified into three groups</title><p>Out of 34 vaccinees, 21 vaccinees seroconverted (an anti-HBs titer above 10 IU/ml was considered protective; <xref ref-type="bibr" rid="bib29">Keating and Noble, 2003</xref>) at day 60 and were classified as early-converters; nine vaccinees seroconverted at day 180 or day 365 and were classified as late-converters; remaining four vaccinees had an anti-HBs antibody titer lower than 10 IU/ml at all time points following vaccination and were classified as non-converters (<xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Hepatitis B vaccination (Engerix-B) study design.</title><p>(<bold>A</bold>) Hepatitis B (Engerix-B) vaccination and experimental design. (Top) Timeline of vaccination and blood collection. (Bottom) Memory CD4 T cells were magnetically enriched and FACS-sorted from two time points (day 0 and day 60) for TCRβ repertoire sequencing. Peptide matrix pools were used to map CD4 T cell epitopes of the vaccine from peripheral blood mononuclear cells (PBMCs) collected at day 60 and to select single peptides. After 7 days of in vitro expansion, single peptide-specific and master peptide pool-specific CFSE<sup>low</sup> CD4 T cells from PBMCs collected at day 60 were FACS-sorted in two technical replicates for TCRβ repertoire sequencing. PBMCs collected at days 0, 60, 180, and 365 were stimulated with the master peptide pool (HBsAg) and assessed for converse expression of 4-1BB and CD40L by flow cytometry. (<bold>B</bold>) Vaccinee cohort can be classified into three groups as determined by anti-hepatitis B surface (anti-HBs) titer over four times points. Early-converters seroconverted at day 60, late-converters seroconverted at day 180 or day 365, and non–converters did not have an anti-HBs titer higher than 10 IU/ml at any of the time points.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68388-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Serological memory to hepatitis B vaccine and vaccinee groups within the cohort.</title><p>(<bold>A</bold>) Anti-hepatitis B surface (anti-HBs) titer of vaccinees over four times points, faceted by groups of early-, late-, and non-converters. An anti-HBs titer above 10 IU/ml was considered protective. Early-converters seroconverted at day 60, late-converters seroconverted at day 180 or day 365, and non–converters did not have an anti-HBs titer higher than 10 IU/ml at any of the time points. (<bold>B</bold>) Cytomegalovirus (CMV), Epstein-Barr virus (EBV), and herpes simplex virus (HSV) seropositivity in the three groups of the cohort as determined by serum IgG antibodies to CMV, EBV viral-capsid antigen (EBV-VCA), and HSV-1 and -2 using sandwich ELISA. (<bold>C</bold>) Age of vaccinees per group. Statistical significance was indicated with ns p &gt; 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68388-fig1-figsupp1-v3.tif"/></fig></fig-group><p>Members of Herpesviridae family might alter immune responses to vaccines (<xref ref-type="bibr" rid="bib23">Furman et al., 2015</xref>). We found no significant differences in cytomegalovirus (CMV), Epstein-Barr virus (EBV), or herpes simplex virus (HSV) seropositivity between the three groups in our cohort (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Early-converters were slightly younger than late-converters, and non-converters were notably younger than both early- and late-converters (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>).</p></sec><sec id="s2-2"><title>Unperturbed diversity in memory CD4 T cell repertoire following vaccination</title><p>A genomic DNA-based TCRβ sequence dataset of memory CD4 T cells isolated from peripheral blood was generated from a cohort of 33 healthy vaccinees (see Materials and methods for details) right before vaccination (day 0) and 60 days after administration of the first dose of HB vaccine (30 days after administration of the second vaccine dose).</p><p>Between 4.54 × 10<sup>4</sup> and 3.92 × 10<sup>5</sup> productive TCRβ sequence reads were obtained for each vaccinee at each time point (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Between 30,000 and 90,000 unique TCRβ sequences were sequenced for each vaccinee at each time point (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). As expected, considering the extremely diverse memory CD4 T cell repertoire (<xref ref-type="bibr" rid="bib31">Klarenbeek et al., 2010</xref>), less than 20% of the TCRβ sequences is shared between the time points for each vaccinee (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>).</p><p>The diversity of the memory CD4 T cell repertoire of each vaccinee at the two time points was explored, but neither the breadth of the memory CD4 TCRβ repertoire nor the Shannon equitability index was found to have been impacted by the vaccine at day 60 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>CD4 T cell memory T cell receptor β (TCRβ) repertoire and vaccine-specific TCRβ clonotypes.</title><p>(<bold>A</bold>) Comparison of the memory CD4 TCRβ repertoire diversity, as shown by breadth (number of unique TCRs) and entropy (Shannon equitability index) between day 0 and day 60. Indices are available in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>. (<bold>B</bold>) Frequency of unique vaccine-specific TCRβ sequences out of total sequenced TCRβ sequences between two time points for all vaccinees colored by group. Frequencies are available in <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>. (<bold>C</bold>) Sequenced CD4<sup>+</sup> TCR memory repertoire of vaccinee H35 at day 60. Each TCR clonotype is represented by a node. TCRs are connected by an edge if their Hamming distance is one. Only clusters with at least three TCRs are shown. TCR clonotypes in red are the vaccine-specific TCRβ sequences that were not present prior to vaccination. (<bold>D</bold>) Frequency of vaccine-specific TCRβ sequences within memory CD4 T cell repertoire normalized by number of HBsAg-specific TCRβ sequences found for each vaccinee at time point 60. Frequencies are available in <xref ref-type="supplementary-material" rid="fig2sdata3">Figure 2—source data 3</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Breadth and entropy of T cell receptor β (TCRβ) repertoire.</title><p>Breadth (number of unique TCRs) and entropy (Shannon equitability index) of the memory CD4 TCRβ repertoire at two time points, day 0 and day 60.</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-68388-fig2-data1-v3.csv"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Frequency of unique hepatitis B surface antigen (HBsAg)-specific T cell receptor β (TCRβ) sequences.</title><p>Frequency of unique HBsAg-specific TCRβ sequences out of unique total TCRβ sequences in the memory CD4 T cell repertoire at two time points, day 0 and day 60.</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-68388-fig2-data2-v3.csv"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Frequency of normalized hepatitis B surface antigen (HBsAg)-specific T cell receptor β (TCRβ) sequences.</title><p>Frequency of vaccine-specific TCRβ sequences within memory CD4 T cell repertoire normalized by number of HBsAg-specific TCRβ sequences found for each vaccinee at day 60.</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-68388-fig2-data3-v3.csv"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68388-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>CD4 T cell memory T cell receptor β (TCRβ) repertoire and vaccine-specific TCRβ clonotypes.</title><p>(<bold>A</bold>) Scatter plot of the DNA-based TCRβ reads for each vaccinee at each time point. (<bold>B</bold>) Scatter plot of number of unique TCRβ amino acid sequences for each vaccinee at each time point, where the shape denotes the response as based on antibody titer. (<bold>C</bold>) Overview of unique TCRβ amino acid sequences in the memory CD4 T cell repertoire of each vaccinee. The bottom blue bar denotes those TCR sequences that were found at both time points. The green and red bars denote the number of unique TCR sequences at each time point. The total bar height thus represents the total number of unique memory CD4 T cell clonotypes sequences for a specific vaccinee. (<bold>D</bold>) Frequency of unique HBsAg-specific TCRβ sequences out of total sequenced TCRβ sequences between two time points for all vaccinees colored and faceted by group. (<bold>E</bold>) Change in frequency (clone read count/total counts) of those HBsAg-specific CD4 T cells present at both time points. The (ns) mark denotes a non-significant paired Wilcoxon signed-rank test (p-value = 0.7577). (<bold>F</bold>) Receiver operating characteristic (ROC) curve using <italic>R<sub>hbs</sub></italic> to differentiate between age-matched early-converters and late-converters in a leave-one-out cross-validation at day 0. Age-matching was accomplished retaining only samples in the age range 40–55. A Wilcoxon test was used to confirm that there was no difference in age distributions between early- and late-converters (p-value = 0.60, mean EC = 44.5 years, mean LC 45.1 years). Diagonal line denotes a random classifier. Reported is the area under the curve (AUC) and its 95% confidence interval.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68388-fig2-figsupp1-v3.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Unique vaccine-specific TCRβ sequences are trackable within memory CD4 T cell repertoire and increase following vaccination</title><p>Peripheral blood mononuclear cells from day 60 were labeled with carboxyfluorescein succinimidyl ester (CFSE), a dye that enables tracking of cell proliferation, and stimulated with a pool of peptides spanning HB surface antigen (HBsAg). After day 7 of in vitro expansion, we sorted CFSE<sup>low</sup> CD4 T cells (<xref ref-type="bibr" rid="bib4">Becattini et al., 2015</xref>) and extracted mRNA for quantitative assessment of HBsAg-specific TCRβ clonotypes by sequencing (see Materials and methods for details). The establishment of a set of vaccine-specific TCRs enables their tracking within memory CD4 T cell repertoires from day 0 to day 60, based on their CDR3β amino acid sequences.</p><p>We detected a significant increase in the breadth of HBsAg-specific TCRβ sequences at day 60 post-vaccination compared to pre-vaccination (mean increase = 107.9%, 95% CI = 62.2–358.5%) (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). This increase far exceeded a baseline control of varicella-zoster virus (VZV)-specific TCRβ sequences established in an identical manner (mean difference = 2.1%, 95% CI = −6.6% to 12.4%). The HBsAg-specific increase was found to be significant when compared to this VZV baseline (Wilcoxon p-value 6.3e-05). When considered across the different groups, the increase was found to be significantly different from the VZV baseline for the early-converters (mean = 151.9%, 95% CI = 78.9–342.0%, Wilcoxon Bonferroni-corrected p-value 8.64e-5) and non-converters (mean = 67.6%, 95% CI: 37.6–89.7%, Wilcoxon Bonferroni-corrected p-value 0.03), but not for the late-converters (mean = 18.8%, 95% CI = 3.6–41.8%, Wilcoxon Bonferroni-corrected p-value 0.257).</p><p>As HBsAg-specific TCRβ sequences were already detected in the memory CD4 T cell repertoire prior to vaccination, we sought to determine whether the vaccination induced an expansion of those sequences. Based on the frequency of vaccine-specific TCRβ sequences within the memory CD4 T cell repertoire, the data does not support a vaccine-induced expansion of preexisting vaccine-specific TCRβ sequences (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). Thus, although we see a rise in vaccine-specific TCRβ T cells from day 0 to day 60, this cannot be attributed to an expansion of the vaccine-specific TCRβ clonotypes found at day 0 but rather the recruitment of new TCRβ clonotypes, as visualized for one vaccinee in <xref ref-type="fig" rid="fig2">Figure 2C</xref>.</p><p>It makes sense to not only look at the difference in vaccine-specific TCRβ sequences between time points, but also explore whether there are differences in the proportion of HBsAg-specific clones in the memory repertoire between early-converters, late-converters, and non-converters after vaccination. In this case, to allow for a between-vaccinees comparison (in contrast to the within-vaccinees time point comparison), we calculate the overlap coefficient, where HBsAg-specific sequences in the CD4 T cell memory repertoire are normalized by the number of HBsAg-specific TCRβ found for each vaccinee. From this analysis, it can be concluded that there is a difference in HBsAg-specific TCRβ at day 60 between the three groups (<xref ref-type="fig" rid="fig2">Figure 2D</xref>) (ANOVA p-value = 0.00238). A Wilcoxon test between early-converters and other vaccinees shows a significant p-value of 0.000473, indicating that early-converters have a higher relative frequency of vaccine-specific TCRβ sequences present in their memory CD4 T cell repertoire at day 60 compared to vaccinees from the two other groups in the cohort.</p><p>In summary, vaccine-specific TCRβ sequences increased in breadth following vaccination in early-converters and constituted a significantly higher proportion of the memory CD4 T cell compartment post-vaccination.</p></sec><sec id="s2-4"><title>HBsAg single peptide-specific TCRβ identification allows predictive modelling of early-converters prior to vaccination</title><p>To quantify the T cell response at the level of individual peptides that make up the HBsAg, a peptide matrix designed to cover 54 overlapping peptides of the HBsAg was used to extract peptide-specific T cells using a CD40L/CD154 activation-induced marker (AIM) assay (see Materials and methods for details). The top six peptides for each individual were selected for an in vitro peptide-specific CD4 T cell expansion and sorting for TCR sequencing (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). In this manner, TCRβ sequences were identified for T cells reactive against 44 single HBsAg peptides. These were not uniformly distributed across the HBsAg amino acid sequence, with the most prominent epitopes covering the regions 1–15, 129–144, 149–164, 161–176, 181–200, 213–228. For each of those regions, more than 10 individuals had a strong T cell response and more than 150 unique TCRβ sequences could be identified (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Hepatitis B surface antigen (HBsAg) peptide-specific T cell receptor β (TCRβ) identification and predictive potential of <italic>R<sub>hbs</sub></italic>.</title><p>(<bold>A</bold>) Overview of the detected HBsAg epitope-specific TCRβ sequences. Each bar corresponds to unique TCRβ sequences found against a single 15mer HBsAg peptide, with 11 amino acid overlap to each subsequent peptide. Bars in blue denote those epitopes for which 10 or more volunteers had a strong T cell reaction. Motif logos on top of bars denote a sampling of the most common TCRβ amino acid sequence motifs for those epitopes. (<bold>B</bold>) Scatter plot with the frequency of predicted HBsAg epitope-specific and bystander TCRβ sequences at day 60. These make up respectively the numerator and denominator of the HBsAg-predictive ratio, <bold><italic>R</italic></bold><italic><sub>hbs</sub></italic>. Predictions done as a leave-one-out cross-validation. Each circle represents a vaccinee with the color denoting the response group (blue: early-converter, yellow: late-converter, red: non-converter). (<bold>C</bold>) HBsAg-predictive ratio, <bold><italic>R</italic></bold><italic><sub>hbs</sub></italic>, when calculated on the memory CD4 TCRβ repertoires at day 60. (<bold>D</bold>) HBsAg-predictive ratio, <bold><italic>R</italic></bold><italic><sub>hbs</sub></italic>, when calculated on the memory CD4 TCRβ repertoires at day 0. (<bold>E</bold>) Receiver operating characteristic (ROC) curve using <bold><italic>R</italic></bold><italic><sub>hbs</sub></italic> to differentiate between early-converters and late-converters in a leave-one-out cross-validation at day 0. Reported is the area under the curve (AUC) and its 95% confidence interval. Data for B, C, D, and E are available in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>. (<bold>F</bold>) ROC curve using <italic>R<sub>hbs</sub></italic> to differentiate between age-matched early-converters and late-converters in a leave-one-out cross-validation at day 0. Age-matching was accomplished retaining only samples in the age range 40–55. A Wilcoxon test was used to confirm that there was no difference in age distributions between early- and late-converters (p-value = 0.60, mean EC = 44.5 years, mean LC 45.1 years). Diagonal line denotes a random classifier. Reported is the area under the curve (AUC) and its 95% confidence interval.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Hepatitis B surface antigen (HBsAg)-predictive ratio (<italic>R<sub>hb</sub></italic>) data.</title><p>Frequency of predicted HBsAg epitope-specific and bystander T cell receptor β (TCRβ) sequences; and HBsAg-predictive ratio, <bold><italic><bold>R</bold></italic></bold><italic><sub>hbs</sub></italic>, calculated on the memory CD4 TCRβ repertoires at two time points, day 0 and day 60.</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-68388-fig3-data1-v3.csv"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68388-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Overview of the outcome of in vitro expansion experiments.</title><p>Shown is the frequency of CFSE<sup>low</sup> CD4 T cells out of total CD4 T cells for all vaccinees, vaccinees per group and for each vaccinee. Peripheral blood mononuclear cells from day 60 were labeled with carboxyfluorescein succinimidyl ester (CFSE) and stimulated with a pool of peptides spanning hepatitis B (HB) surface antigen (HBsAg) (peptide pool) and single peptides selected based on epitope mapping of the entire antigen (single peptide). After day 7 of in vitro expansion, cells were stained with antibodies to surface markers (CD3, CD4, and CD8) that enable gating on viable CD4 T cells. CFSE intensity was used to identify and sort CFSE<sup>low</sup> cells for T cell receptor (TCR) repertoire analysis of antigen-specific CD4 T cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68388-fig3-figsupp1-v3.tif"/></fig></fig-group><p>These peptide-specific TCRβ sequences can be utilized in a peptide-TCR interaction classifier to identify other TCRβ that are likely to react against same HBsAg epitopes, as it has been shown that similar TCRβ sequences tend to target the same epitopes (<xref ref-type="bibr" rid="bib13">De Neuter et al., 2018</xref>; <xref ref-type="bibr" rid="bib41">Meysman et al., 2019</xref>). These classifications were integrated into a model which outputs a ratio <italic>R<sub>hbs</sub></italic>, which represents the amount of HBsAg epitope-specific TCR sequences in an individual repertoire. The ratio is equal to the breadth of unique predicted HBsAg peptide-specific TCRβ divided by a normalization term for putative false positive predictions due to bystander activations in the training data set. The memory repertoire at day 60 shows that early-converters tend to have a higher breadth of putative HBsAg peptide-specific TCRβ, while late-converters tend to have relatively more putative false positives as per the normalization term (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The ratio of these two terms <italic>R<sub>hbs</sub></italic> therefore shows a significant difference between early- and the late-converters at day 60 (one-sided Wilcoxon-test p-value = 0.0313, <xref ref-type="fig" rid="fig3">Figure 3C</xref>). Furthermore, searching for HBsAg peptide-specific clonotypes in the memory repertoires prior to vaccination (day 0) results in a <italic>R<sub>hbs</sub></italic> with a similar difference (one-sided Wilcoxon-test p-value = 0.0010, <xref ref-type="fig" rid="fig3">Figure 3D</xref>). In this manner, the presence of HBsAg peptide-specific clonotypes as defined by the ratio <italic>R<sub>hbs</sub></italic> can be used as a classifier to distinguish early- from late-converters prior to vaccination (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), with an area under the curve (AUC) of 0.825 (95% CI: 0.657–0.994) in a leave-one-out cross-validation setting. A model in which age-matched vaccinees were included from early- and late-converters returned a similar receiver operating characteristic (ROC) curve, suggesting that this signal is not age-dependent (<xref ref-type="fig" rid="fig3">Figure 3F</xref>).</p><p>While <italic>R<sub>hbs</sub></italic> is able to differentiate between early- and late-converters, it seems to be worse at distinguishing non-converters. This is mainly due to a single non-converter vaccinee (H21) with a high <italic>R<sub>hbs</sub></italic>, signifying a high number of putative HBsAg peptide-specific TCRβ in their memory repertoire.</p></sec><sec id="s2-5"><title>Vaccine-specific conventional and regulatory memory CD4 T cells induced in early-converters</title><p>After showing evidence for the existence of vaccine-specific TCRβ sequences pre-vaccination and that individuals with a higher number of HBsAg peptide-specific clonotypes had earlier seroconversion, we attempted to link this observation to differences in vaccine-specific CD4 T cells responses using CD4 T cell assays. As T<sub>REG</sub> cells might suppress vaccine-induced immune responses (<xref ref-type="bibr" rid="bib8">Brezar et al., 2016</xref>), we used activation markers CD40L (CD154) and 4-1BB (CD137) to help delineate the conventional (T<sub>CON</sub>) and regulatory (T<sub>REG</sub>) phenotypes of activated CD4 T cells. In this scheme, after 6 hr of antigen stimulation, CD40L<sup>+</sup>4-1BB<sup>−</sup> can be used as a signature for antigen-specific CD4 T<sub>CON</sub> cells, as opposed to CD40L<sup>−</sup>4-1BB<sup>+</sup> signature for antigen-specific CD4 T<sub>REG</sub> cells (<xref ref-type="bibr" rid="bib17">Elias et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">Schoenbrunn et al., 2012</xref>). Additionally, we added CD25 and CD127 to better identify T<sub>REG</sub> cells (<xref ref-type="bibr" rid="bib36">Liu et al., 2006</xref>; <xref ref-type="bibr" rid="bib57">Seddiki et al., 2006</xref>) and CXCR5 to further distinguish circulatory T follicular helper cells (cT<sub>FH</sub>) and circulatory T follicular regulatory cells (cT<sub>FR</sub>) (<xref ref-type="bibr" rid="bib5">Bentebibel et al., 2011</xref>; <xref ref-type="bibr" rid="bib21">Fonseca et al., 2017</xref>) (see <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> for gating strategy).</p><p>Using the converse expression of CD40L and 4-1BB, CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> CD4 T cells have a CD25<sup>low</sup>CD127<sup>high</sup> and CD25<sup>high</sup>CD127<sup>low</sup> phenotype, respectively (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), and validate their use for the distinction of activated T<sub>CON</sub> and T<sub>REG</sub> cells as described before (<xref ref-type="bibr" rid="bib56">Schoenbrunn et al., 2012</xref>).</p><p>We detected a significant increase in the frequency of vaccine-specific CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> memory CD4 T cells at day 60 in our cohort (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) that correlated positively with the increase in antibody titer between day 0 and day 365 (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). Upon a closer look, the induction of both signatures of vaccine-specific memory CD4 T cells was only true for early-converters (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, see <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A</xref> for non-converters and <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4B</xref> for vaccine-specific CD4 T cells). Late-converters did not show a detectable memory CD4 T cell response. Although a subset of both early- and late-converters had detectable memory CD4 T cell responses prior to vaccination, we observed no significant differences in the frequencies of CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> memory CD4 T cells between the two groups at day 0 (<xref ref-type="fig" rid="fig4">Figure 4D</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Hepatitis B vaccine induces a vaccine-specific CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> memory CD4 T cell response in early-converter vaccinees.</title><p>Peripheral blood mononuclear cells (PBMCs) from vaccinees were stimulated with 2 μg/ml of the master peptide pool (hepatitis B surface antigen [HBsAg]) and assessed for converse expression of 4-1BB and CD40L by flow cytometry on days 0, 60, 180, and 365. Shown is number of vaccine-specific memory CD4 T cells out of 10<sup>6</sup> memory CD4 T cells after subtraction of responses in negative control. (<bold>A</bold>) Aggregate analysis from vaccinees (including early-, late-, and non-converters) showing a peak of vaccine-specific CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> memory CD4 T cell at day 60 (day 60 after first dose of the vaccine and day 30 after second dose), declining thereafter. Shown are numbers of vaccine-specific memory CD4 T cells out of 10<sup>6</sup> memory CD4 T cells. (<bold>B</bold>) Correlation between the difference in antibody titer between day 365 and day 0 and vaccine-specific CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> memory CD4 T cell at day 60. (<bold>C</bold>) Aggregate analysis from early- and late-converter vaccinees showing a significant induction of vaccine-specific CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> memory CD4 T cell in early-converters and lack thereof in late-converters. (<bold>D</bold>) Aggregate analysis from early- and late-converter vaccinees showing no significant differences in vaccine-specific CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> memory CD4 T cell at day 0. Data for A, B, C, and D are available in <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>. (<bold>E</bold>) Receiver operating characteristic (ROC) curves for <bold><italic>R</italic></bold><italic><sub>hbs</sub></italic> from day 0 data in a leave-one-out cross-validation compared to the frequency of vaccine-specific CD40L<sup>+</sup>4-1BB<sup>−</sup> memory CD4 T cell out of 10<sup>6</sup> memory CD4 T cells for each vaccinee at time points 60 (area under the curve [AUC] = 0.84), 180 (AUC = 0.56), and 365 (AUC = 0.57). (<bold>F</bold>) Receiver operating characteristic (ROC) curves for <bold><italic>R</italic></bold><italic><sub>hbs</sub></italic> from day 0 data in a leave-one-out cross-validation compared to the frequency of vaccine-specific CD40L<sup>−</sup>4-1BB<sup>+</sup> memory CD4 T cell out of 10<sup>6</sup> memory CD4 T cells for each vaccinee at time points 60 (AUC = 0.62), 180 (AUC = 0.56), and 365 (AUC = 0.52). Statistical significance was indicated with ns p &gt; 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 <italic>rs</italic>, Spearman’s correlation coefficient, −1≤ <italic>rs</italic> ≤ 1; <italic>rs</italic> and p-value by Spearman’s correlation test.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Ex vivo T cell assay and serological data.</title><p>Numbers of vaccine-specific CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> memory CD4 T cell out of 10<sup>6</sup> memory CD4 T cells and antibody titers at the four time points, days 0, 60, 180, and 365.</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-68388-fig4-data1-v3.csv"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68388-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Gating strategy of ex vivo T cell phenotyping of vaccine-specific T cells.</title><p>(<bold>A</bold>) Gating strategy started by a lymphocyte gate, followed by gating on viable CD3<sup>+</sup>CD8<sup>−</sup> T cells. Doublets were excluded using doublet discrimination (area against the height of forward scatter pulse) before gating on CD4<sup>+</sup> T cells. Next, CD45RA, CXCR5, CD25, and CD127 were used to identify main subsets of CD4 T cells using Boolean gates as specified in the accompanying table. (<bold>B</bold>) Shown an example of gating for CD154 (CD40L) and CD137 (4-1BB) for cells left unstimulated (left) and cells stimulated with a master peptide pool (right) for an early-converter vaccinee at day 60.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68388-fig4-figsupp1-v3.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> CD4 T cells have a T<sub>CON</sub> and T<sub>REG</sub> phenotype, respectively.</title><p>Peripheral blood mononuclear cells (PBMCs) from vaccinees were stimulated with 2 μg/ml of a pool of peptides of hepatitis B surface antigen (HBsAg) and assessed for converse expression of 4-1BB and CD40L by flow cytometry. (<bold>A</bold>) CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> CD4 T cells from day 60 were gated on and then overlaid in a contour plots of CD25 versus CD127 to assess T<sub>COV</sub> and T<sub>REG</sub> phenotype. (<bold>B</bold>) Summary plot of median fluorescence intensity (MFI) of CD25 and CD127 for all vaccinees. Wilcoxon signed-rank with paired analysis; statistical significance was indicated with ****p ≤ 0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68388-fig4-figsupp2-v3.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Relationship between serological memory and memory CD4 T cell response to the vaccine.</title><p>Correlation between the difference in antibody titer between day 365 and day 0 and vaccine-specific CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> memory CD4 T cell at day 60 colored by vaccinee group and labeled with vaccinee ID. <italic>rs</italic>, Spearman’s correlation coefficient, −1≤ <italic>rs</italic> ≤ 1; <italic>rs</italic> and p-value by Spearman’s correlation test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68388-fig4-figsupp3-v3.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Hepatitis B vaccine induces a vaccine-specific CD4 T cell response in early-converter vaccinees.</title><p>Peripheral blood mononuclear cells (PBMCs) from vaccinees were stimulated with 2 μg/ml of a pool of peptides of hepatitis B surface antigen (HBsAg) and assessed for converse expression of 4-1BB and CD40L by flow cytometry on days 0, 60, 180, and 365. (<bold>A</bold>) Aggregate analysis from early-, late-, and non-converter vaccinees showing a significant induction of vaccine-specific CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> memory CD4 T cell in early-converters and lack thereof in late and non-converters. Shown are numbers of vaccine-specific memory CD4 T cells out of 10<sup>6</sup> memory CD4 T cells after subtraction of responses in negative control (see Materials and methods for details). (<bold>B</bold>) Aggregate analysis from early-, late-, and non-converter vaccinees showing a significant induction of vaccine-specific CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> CD4 T cell in early-converters and lack thereof in late and non-converters. Shown are numbers of vaccine-specific CD4 T cells out of 10<sup>6</sup> CD4 T cells after subtraction of responses in negative control (see Materials and methods for details).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68388-fig4-figsupp4-v3.tif"/></fig></fig-group><p>Collectively, flow cytometry data reveal that the expression of CD40L and 4-1BB in our ex vivo assay is consistent with our serological data and reflects the lack of seroconversion at day 60 in late-converters. However, it does not support the existence of more vaccine-specific memory CD4 T cells in early-converters prior to vaccination.</p></sec><sec id="s2-6"><title>Predictive capacity of TCRβ repertoire holds true for CD4 T<sub>CON</sub> immune response</title><p>Response groups used so far were established based on the dynamics of anti-HBs titers following vaccination. However, response groups can be defined based on the data of antigen specificity from the ex vivo CD4 T cell assay. Thus the frequency of CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> memory CD4 T cells were used to define a low and high response group at three different times points (days 60, 180, and 365). For each time point, the same <italic>R<sub>hbs</sub></italic> metric was used in a leave-one-out cross-validation as before to differentiate between these novel response group definitions. Results indicate that the <italic>R<sub>hbs</sub></italic> metric is a good predictor for HBsAg-specific memory CD4 T cells with a T<sub>CON</sub> signature (but not T<sub>REG</sub> signature) identified at day 60 post-vaccination (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>). However, the classifier is less performant for the prediction of CD4 T cell response at later time points.</p></sec><sec id="s2-7"><title>An expanded subset of 4-1BB<sup>+</sup>CD45RA<sup>−</sup> T<sub>REG</sub> cells is a prominent feature of late-converters</title><p>In order to detect any distinct signatures of early- and late-converters, we analyzed pre-vaccination flow cytometry data to examine major CD4 T cell subsets: T<sub>H</sub>, T<sub>REG</sub>, cT<sub>FH</sub>, and cT<sub>FR</sub> cells.</p><p>Using manual gating in which regulatory T cells (T<sub>REG</sub>) were defined as viable CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>−</sup>CD25<sup>+</sup>CD127<sup>−</sup>CXCR5<sup>−</sup> and were further divided into CD45RA<sup>+</sup> and CD45RA<sup>−</sup> T<sub>REG</sub> cells, we identified a significantly higher frequency of 4-1BB<sup>+</sup> CD45RA<sup>−</sup> T<sub>REG</sub> cells in late-converters compared to early-converters (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>An expanded 4-1BB<sup>+</sup>CD45RA<sup>−</sup> T<sub>REG</sub> cells within T<sub>REG</sub> compartment is a prominent feature in late-converters prior to vaccination.</title><p>Peripheral blood mononuclear cells (PBMCs) from vaccinees at day 0 (prior to vaccination) were phenotyped for expression of markers of T<sub>REG</sub>. (<bold>A</bold>) Aggregate analysis of 4-1BB<sup>+</sup>CD45RA<sup>−</sup> T<sub>REG</sub> within CD45RA<sup>−</sup> T<sub>REG</sub> CD4 T cells in early- and late- and non-converter vaccinees before vaccination. (<bold>B</bold>) Aggregate analysis of the median fluorescence intensity of 4-1BB in T<sub>H</sub>, cT<sub>FH</sub>, T<sub>REG</sub>, and cT<sub>FR</sub> cells before vaccination. (<bold>C</bold>) Aggregate analysis of the median fluorescence intensity of 4-1BB (left panel) and CD25 (right panel) in CD45RA<sup>−</sup> T<sub>REG</sub> and CD45RA<sup>+</sup> T<sub>REG</sub> cells before vaccination. Data for A, B, and C are available in <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>. (<bold>D</bold>) Frequency of T<sub>REG</sub>, CD45RA<sup>−</sup> T<sub>REG</sub>, and CD45RA<sup>+</sup> T<sub>REG</sub> cells within total CD4 T cells in early-, late-, and non-converter vaccinees before vaccination. (<bold>E</bold>) Composition of T<sub>REG</sub> compartment as determined by expression of 4-1BB and CD45RA in early-, late-, and non-converter vaccinees before vaccination. Statistical significance was indicated with ns p &gt; 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Frequency of 4-1BB<sup>+</sup>CD45RA<sup>−</sup> T<sub>REG</sub> cells and median fluorescence intensity data.</title><p>Frequency of 4-1BB<sup>+</sup>CD45RA<sup>−</sup> T<sub>REG</sub> within CD45RA− T<sub>REG</sub> CD4 T cells, and median fluorescence intensity of 4-1BB in T<sub>H</sub>, cT<sub>FH</sub>, T<sub>REG</sub>, and cT<sub>FR</sub> cells, and of 4-1BB and CD25 in CD45RA<sup>−</sup> T<sub>REG</sub> and CD45RA<sup>+</sup> T<sub>REG</sub> cells before vaccination.</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-68388-fig5-data1-v3.csv"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68388-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>An expanded 4-1BB<sup>+</sup>CD45RA<sup>−</sup> T<sub>REG</sub> cells within T<sub>REG</sub> compartment is a prominent feature in late-converters prior to vaccination.</title><p>Aggregate analysis of the frequency of 4-1BB<sup>+</sup>CD45RA<sup>−</sup> T<sub>REG</sub> within CD45RA<sup>−</sup> T<sub>REG</sub> CD4 T cells in early-, late-, and non-converter vaccinees at days 0, 60, 180, and 365. Statistical significance was indicated with ns p &gt; 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68388-fig5-figsupp1-v3.tif"/></fig></fig-group><p>T<sub>REG</sub> cells showed higher 4-1BB expression compared to T<sub>H</sub>, cT<sub>FH</sub>, and cT<sub>FR</sub> cells (<xref ref-type="fig" rid="fig5">Figure 5B</xref>) and within T<sub>REG</sub> subset, CD45RA<sup>−</sup> T<sub>REG</sub> cells showed significantly higher expression of 4-1BB, accompanied with a higher expression of CD25, compared to CD45RA<sup>+</sup> T<sub>REG</sub> cells (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). In this scheme, CD45RA<sup>−</sup> T<sub>REG</sub> can be divided into 4-1BB<sup>+</sup>CD25<sup>high</sup> and 4-1BB<sup>-</sup>CD25<sup>int</sup> subsets. It is worth noting here that no differences were detected in the frequency of CD45RA<sup>−</sup> or CD45RA<sup>+</sup> T<sub>REG</sub> cells within CD4 T cell compartment between the two groups (<xref ref-type="fig" rid="fig5">Figure 5D</xref>), and that it is the composition of T<sub>REG</sub> compartment that is distinct between the two groups (<xref ref-type="fig" rid="fig5">Figure 5E</xref>).</p><p>In summary, an expanded subset of 4-1BB<sup>+</sup>CD45RA<sup>−</sup> T<sub>REG</sub> cells pre-vaccination is a prominent feature of a delayed and modest immune response to HB vaccine in our cohort.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we used high-throughput TCRβ repertoire profiling and ex vivo T cell assays to characterize memory CD4 T cell repertoires before and after immunization with HB vaccine, an adjuvanted subunit vaccine, and tracked vaccine-specific TCRβ clonotypes over two time points. As antigen-naïve adults were found to have an unexpected abundance of memory-phenotype CD4 T cells specific to viral antigens (<xref ref-type="bibr" rid="bib60">Su and Davis, 2013</xref>; <xref ref-type="bibr" rid="bib61">Su et al., 2013</xref>), we sought to investigate the influence that preexisting memory CD4 T cells can have on vaccine-induced immunity.</p><p>Commercially available HBV vaccines produce a robust and long-lasting anti-HBs response, and protection is provided by induction of an anti-HBs (antibody against HBV surface antigen) titer higher than 10 mIU/ml after a complete immunization schedule of three doses (<xref ref-type="bibr" rid="bib40">Meireles et al., 2015</xref>). However, 5–10% of healthy adult vaccinees fail to produce protective titers of anti-HBs and can be classified as non-responders (<xref ref-type="bibr" rid="bib40">Meireles et al., 2015</xref>). In our cohort, 13 vaccinees did not seroconvert by day 60 (30 days following administration of the second vaccine dose), as determined by antibody titer. Out of this group, nine vaccinees seroconverted by day 180 or day 365, referred to here as late-converters, and four vaccinees did not seroconvert, referred to here as non-converters.</p><p>A hallmark of adaptive immunity is a potential for memory immune responses to increase in both magnitude and quality upon repeated exposure to the antigen (<xref ref-type="bibr" rid="bib54">Sallusto et al., 2010</xref>). Our systems immunology data supports the theory that preexisting memory CD4 T cell TCRβ sequences specific to HBsAg, the antigenic component of the current HB vaccine, predict which individuals will mount an early and more vigorous immune response to the vaccine as evidenced by a higher fold change in anti-HBs antibody titer and a more significant induction of antigen-specific CD4 T cells. It is postulated that preexisting memory CD4 T cell clonotypes are generated due to the highly degenerate nature of T cell recognition of antigen/MHC and are cross-reactive to environmental antigens (<xref ref-type="bibr" rid="bib58">Sewell, 2012</xref>). For example, preexisting memory CD4 T cells are well-established in unexposed HIV-seronegative individuals, although at a significantly lower magnitude than HIV-exposed seronegative individuals (<xref ref-type="bibr" rid="bib9">Campion et al., 2014</xref>; <xref ref-type="bibr" rid="bib50">Ritchie et al., 2011</xref>), and were likely primed by exposure to environmental triggers or the human microbiome.</p><p>We and others have shown before that the TCRβ repertoire of CD4 T cells encodes the antigen exposure history of each individual and that antigen-specific TCRβ sequences could serve to automatically annotate the infection or exposure history (<xref ref-type="bibr" rid="bib16">DeWitt et al., 2018</xref>; <xref ref-type="bibr" rid="bib18">Emerson et al., 2017</xref>; <xref ref-type="bibr" rid="bib14">De Neuter et al., 2019</xref>). In this study, we show that similar principles can be used to study vaccine responsiveness. Specifically, the recruitment of novel vaccine-specific T cell clonotypes into memory compartment following vaccination can be tracked by examining the CD4 memory TCRβ repertoire over time. While we observed no increase in the frequency of the vaccine-specific memory T cells, as the time point may have missed the peak of the clonal expansion of effector CD4 T cells as was reported before (<xref ref-type="bibr" rid="bib6">Blom et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">Kohler et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Pogorelyy et al., 2018</xref>), a significant rise in the number of unique vaccine-specific T cell clonotypes was detected. This observation is consistent with earlier studies of T cell immune repertoire that showed that antigen-specific TCRβ sequences do not always overlap with those sequences that increase in frequency after infection or vaccination (<xref ref-type="bibr" rid="bib15">DeWitt et al., 2015</xref>). More interestingly, individuals with the earlier and more robust response against the vaccine had a telltale antigen-specific signature in their memory TCRβ repertoire prior to vaccination, despite the lack of HBsAg antibodies and prior vaccination history.</p><p>Detection of this vaccine-specific signature was possible due to the development of a novel predictive model that used epitope-specific TCRβ sequences from one set of individuals to make predictions about another. This is a non-trivial task as the MHC class II molecules vary between vaccinees, which in turn allows for great variation of the presented epitopes. However, we were able to cover the entire HBsAg and obtained a sufficient sample size to likely cover the most immunoprevalent epitopes. It can be presumed that we do not capture the full HBsAg T cell response, but obtain enough sequences which are representative for the response as a whole. In addition, a correction factor was needed to account for the occurrence of bystander-activated T cells within the original epitope-specific TCRβ sequences. Indeed, in those vaccinees without an early seroconversion (at day 60), putative vaccine-specific T cells might be induced due to bystander activation. This was supported by predictions using the TCRex tool (<xref ref-type="bibr" rid="bib26">Gielis et al., 2019</xref>), which matched these TCR sequences to common viral or other epitopes. It is of note that these TCRβ sequences are matched with CD8 T cell epitopes, while they originate from isolated CD4 T cells. This is likely due to the great similarity between the TCRβ sequences of CD4 and CD8 T cells as noted in prior research (<xref ref-type="bibr" rid="bib13">De Neuter et al., 2018</xref>).</p><p>However, our in vitro antigen-specific data, using an assay that enables discrimination of T<sub>CON</sub> and T<sub>REG</sub> cells using the converse expression of the activation markers CD40L and 4-1BB (<xref ref-type="bibr" rid="bib22">Frentsch et al., 2005</xref>; <xref ref-type="bibr" rid="bib56">Schoenbrunn et al., 2012</xref>), failed to show a significant difference in preexisting antigen-specific CD4 T cells between early- and late-converters prior to vaccine administration. It is plausible that our activation proteins, CD40L and 4-1BB, might be unsuitable to detect preexisting memory CD4 T cells but this is unlikely as both proteins were used successfully in similar studies (<xref ref-type="bibr" rid="bib2">Bacher et al., 2014a</xref>; <xref ref-type="bibr" rid="bib3">Bacher et al., 2014b</xref>).</p><p>Another plausible explanation is that the signal is below the detection limit of the assay and that more sensitive techniques that require pre-enrichment of CD40L<sup>+</sup> and 4-1BB<sup>+</sup> T cells (using magnetic beads) (<xref ref-type="bibr" rid="bib1">Bacher et al., 2013</xref>) or cultured ELISpot assay (<xref ref-type="bibr" rid="bib48">Reece et al., 2004</xref>) are needed to capture preexisting vaccine-specific memory CD4 T cells directly from human peripheral blood. A similar disagreement between B cell receptor clonotype diversity underlying vaccine-induced response and a conventional B cell ELISpot assay was reported before following HB vaccination (<xref ref-type="bibr" rid="bib24">Galson et al., 2016</xref>).</p><p>T<sub>REG</sub> cells represent about 5–10% of human CD4 T cell compartment and are identified by the constitutive surface expression of CD25, also known as IL-2 receptor α subunit (IL-2Ra), and the nuclear expression of forkhead family transcription factor 3 (Foxp3), a lineage specification factor of T<sub>REG</sub> cells (<xref ref-type="bibr" rid="bib52">Rudensky, 2011</xref>). Regulatory memory T cells play a role in the mitigation of tissue damage induced by effector memory T cells during protective immune responses, resulting in a selective advantage against pathogen-induced immunopathology (<xref ref-type="bibr" rid="bib25">Garner-Spitzer et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">Lanteri et al., 2009</xref>; <xref ref-type="bibr" rid="bib35">Lin et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Lovelace and Maecker, 2018</xref>). Several studies have identified CD4 T<sub>REG</sub> cells with specificity to pathogen-derived peptides in murine models and showed evidence for an induced expansion of T<sub>REG</sub> cells followed by an emergence and a long-term persistence of T<sub>REG</sub> cells with a memory phenotype and potent immunosuppressive properties (<xref ref-type="bibr" rid="bib35">Lin et al., 2018</xref>; <xref ref-type="bibr" rid="bib55">Sanchez et al., 2012</xref>). Blom et al. reported a significant and transient activation of T<sub>REG</sub> cells (identified by upregulation of CD38 and Ki67) in humans 10 days after administration of live attenuated yellow fever virus 17D vaccine (<xref ref-type="bibr" rid="bib6">Blom et al., 2013</xref>). The induction of vaccine-specific T<sub>REG</sub> cells in our cohort is unexpected and the role it might play in vaccine-induced immunity warrants further investigation.</p><p>The association of an expanded 4-1BB<sup>+</sup> CD45RA<sup>−</sup> T<sub>REG</sub> subset with a delayed immune response to HB vaccine was not described before. Miyara et al. showed that blood contains two distinct subsets of stable and suppressive T<sub>REG</sub> cells: resting T<sub>REG</sub>, identified as FOXP3<sup>low</sup>CD45RA<sup>+</sup> CD4 T cells, and activated T<sub>REG</sub>, identified as FOXP3<sup>high</sup>CD45RA<sup>−</sup> CD4 T cells. They further noted that activated T<sub>REG</sub> cells constitute a minority subset within cord blood T<sub>REG</sub> cells and increase gradually with age (<xref ref-type="bibr" rid="bib44">Miyara et al., 2009</xref>). As activated T<sub>REG</sub> cells were shown to have an increased expression of proteins indicative of activation, including ICOS and HLA-DR (<xref ref-type="bibr" rid="bib7">Booth et al., 2010</xref>; <xref ref-type="bibr" rid="bib27">Ito et al., 2008</xref>; <xref ref-type="bibr" rid="bib38">Mason et al., 2015</xref>; <xref ref-type="bibr" rid="bib44">Miyara et al., 2009</xref>; <xref ref-type="bibr" rid="bib45">Mohr et al., 2018</xref>), it might be the case that an upregulation of 4-1BB is one more feature of this population or a subset thereof. Moreover, T<sub>REG</sub> cells in mice were shown to modulate T<sub>FH</sub> formation and germinal center (GC) B cell responses and to diminish antibody production in a CTLA-4 mediated suppression (<xref ref-type="bibr" rid="bib66">Wing et al., 2014</xref>). Interestingly, CD45RA<sup>−</sup> T<sub>REG</sub> cells were shown to be more rich in preformed CTLA-4 stored in intracellular vesicles compared to CD45RA<sup>+</sup> T<sub>REG</sub> cells (<xref ref-type="bibr" rid="bib44">Miyara et al., 2009</xref>).</p><p>4-1BB was shown to be constitutively expressed by T<sub>REG</sub> cells (<xref ref-type="bibr" rid="bib39">McHugh et al., 2002</xref>) and that 4-1BB<sup>+</sup> T<sub>REG</sub> cells are functionally superior to 4-1BB<sup>−</sup> T<sub>REG</sub> cells in both contact-dependent and contact-independent immunosuppression (<xref ref-type="bibr" rid="bib28">Kachapati et al., 2012</xref>). 4-1BB<sup>+</sup> T<sub>REG</sub> cells are the major producers of the alternatively spliced and soluble isoform of 4-1BB among T cells (<xref ref-type="bibr" rid="bib28">Kachapati et al., 2012</xref>). 4-1BB was shown before to be preferentially expressed on T<sub>REG</sub> cells compared with other non-regulatory CD4 T cell subsets (<xref ref-type="bibr" rid="bib39">McHugh et al., 2002</xref>) and that 4-1BB-costimualtion induces the expansion of T<sub>REG</sub> cells both in vitro and in vivo (<xref ref-type="bibr" rid="bib70">Zheng et al., 2004</xref>). Moreover, agonistic anti-4-1BB mAbs have been shown to abrogate T cell-dependent antibody responses in vivo (<xref ref-type="bibr" rid="bib43">Mittler et al., 1999</xref>) and to ameliorate experimental autoimmune encephalomyelitis by skewing the balance against T<sub>H</sub>17 differentiation in favor of T<sub>REG</sub> differentiation (<xref ref-type="bibr" rid="bib30">Kim et al., 2011</xref>). It is plausible that the expansion 4-1BB<sup>+</sup>CD45RA<sup>−</sup> T<sub>REG</sub> cells in late-converters is involved in the suppression of GC vaccine-specific T<sub>FH</sub> cells and the ensuing antibody response in our cohort, but this remains speculative and further research is warranted.</p><p>It is enticing to speculate that the preexisting memory CD4 T cells result from the complex interplay between cellular immunity and the human microbiome. A role for the microbiota in modulating immunity to viral infection was suggested in 1960s (<xref ref-type="bibr" rid="bib51">Robinson and Pfeiffer, 2014</xref>), and since then we gained better understanding of the impact of the various components of the microbiota including bacteria, fungi, protozoa, archaea, and viruses on the murine and human immune systems (<xref ref-type="bibr" rid="bib67">Winkler and Thackray, 2019</xref>).</p><p>Viral clearance of HB virus infection depends on the age of exposure and neonates and young children are less likely to spontaneously clear the virus (<xref ref-type="bibr" rid="bib69">Yuen et al., 2018</xref>). Han-Hsuan et al. have shown evidence in mice that this age dependency is mediated by gut microbiota that prepare the liver immunity system to clear HBV, possibly via a TLR4 signaling pathway (<xref ref-type="bibr" rid="bib10">Chou et al., 2015</xref>). In this study, young mice that have not reached an equilibrium in the gut microbiota exhibited prolonged HBsAg persistence, impaired anti-HBs antibody production, and limited Hepatitis B core antigen (HBcAg)-specific IFNγ<sup>+</sup> splenocytes. More recently, Tingxin et al. provided evidence for a critical role of the commensal microbiota in supporting the differentiation of GC B cells, through follicular T helper (T<sub>FH</sub>) cells, to promote the anti-HBV humoral immunity (<xref ref-type="bibr" rid="bib68">Wu et al., 2019</xref>).</p><p>Our study bears some intrinsic limitations. A major drawback is the restricted number of days at which TCRβ repertoire was profiled, as vaccine-specific perturbations within the repertoire may occur at different time points for early-, late-, and non-converters. Additionally, more in-depth characterization and functional studies on 4-1BB<sup>+</sup>CD45RA<sup>−</sup> T<sub>REG</sub> cells could have helped shed more light on the role they play in vaccine-induced immunity. Future studies in larger cohorts and with a more comprehensive TCRβ repertoire profiling and CD4 T cells immunophenotyping are required to validate our findings.</p><p>In conclusion, our analysis of the memory CD4 T cell repertoire has uncovered a role for preexisting memory CD4 T cells in naïve individuals in mounting an earlier and more vigorous immune response to HB vaccine and argue for the utility of pre-vaccination TCRβ repertoire in the prediction of vaccine-induced immunity. Moreover, we identify a subset of 4-1BB<sup>+</sup> memory T<sub>REG</sub> cells that is expanded in individuals with delayed immune response to the vaccine, which might further explain the heterogeneity of response to HB vaccine.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD3-BV510 (SK7) (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 344828</td><td align="left" valign="bottom">FACS (1/20 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD3-PerCP (BW264/56) (mouse monoclonal)</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-113-131</td><td align="left" valign="bottom">FACS (1/50 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD4-APC (REA623) (recombinant antibodies, REAfinity)</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-113-222</td><td align="left" valign="bottom">FACS (1/50 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD4-APC (RPA-T4) (mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 555349</td><td align="left" valign="bottom">FACS (1/5 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD4-PerCP/Cy5.5 (RPA-T4) (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 300530</td><td align="left" valign="bottom">FACS (1/20 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD8-VioGreen (REA734) (recombinant antibodies, REAfinity)</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-110-684</td><td align="left" valign="bottom">FACS (1/50 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD8-Pacific Orange (3B5) (mouse monoclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# MHCD0830</td><td align="left" valign="bottom">FACS (1/20 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD8-APC/Cy7 (SK1) (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 344714</td><td align="left" valign="bottom">FACS (1/20 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD40L-PE (5C8) (mouse monoclonal)</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-092-289</td><td align="left" valign="bottom">FACS (1/10 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CXCR5-PE-Cy7 (MU5UBEE) (mouse monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 25-9185-42</td><td align="left" valign="bottom">FACS (7/100 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD45RA-AF488 (HI100) (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 304114</td><td align="left" valign="bottom">FACS (1/20 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD45RO-PE (UCHT1) (mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 555493</td><td align="left" valign="bottom">FACS (1/5 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD25-BV421 (M-A251) (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 356114</td><td align="left" valign="bottom">FACS (1/20 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD127-BV785 (A019D5) (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 351330</td><td align="left" valign="bottom">FACS (1/20 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD137-PE (4B4-1) (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 309804</td><td align="left" valign="bottom">FACS (1/20 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD154-APC (5C8) (mouse monoclonal)</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-113-603</td><td align="left" valign="bottom">FACS (3/100 per test)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD40 (HB14) (mouse monoclonal)</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-094-133</td><td align="left" valign="bottom">Assay (1 µg/ml)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CD28 (CD28.2) (mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 556620</td><td align="left" valign="bottom">Assay (1 μg/ml)</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Single peptides of HBsAg</td><td align="left" valign="bottom">JPT Peptide Technologies</td><td align="left" valign="bottom">Customized</td><td align="left" valign="bottom">54 single peptides</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Peptide matrix pools of HBsAg</td><td align="left" valign="bottom">JPT Peptide Technologies</td><td align="left" valign="bottom">Customized</td><td align="left" valign="bottom">A set of 15 matrix pools each with 7–8 peptides</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Master peptide pool of HBsAg</td><td align="left" valign="bottom">JPT Peptide Technologies</td><td align="left" valign="bottom">Customized</td><td align="left" valign="bottom">A pool of 54 single peptides</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CD4 MicroBeads</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-045-101</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">DNA/RNA Shield</td><td align="left" valign="bottom">Zymo Research</td><td align="left" valign="bottom">Cat# R1100-50</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Quick-DNA Microprep kit</td><td align="left" valign="bottom">Zymo Research</td><td align="left" valign="bottom">Cat# D3020</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">ImmunoSEQ hsTCRB sequencing kit</td><td align="left" valign="bottom">Adaptive Biotechnologies</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Quick-RNA Microprep kit</td><td align="left" valign="bottom">Zymo Research</td><td align="left" valign="bottom">Cat# R1050</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">QIAseq Immune Repertoire RNA Library kit</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">Cat# 333705</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Qubit dsDNA HS Assay</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# Q32854</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo version 10.5.3</td><td align="left" valign="bottom">Tree Star</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002865">SCR_002865</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">immunoSEQ analyzer (v2)</td><td align="left" valign="bottom">Adaptive Biotechnologies</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">TCRex web-based</td><td align="left" valign="bottom">(<xref ref-type="bibr" rid="bib26">Gielis et al., 2019</xref>), <ext-link ext-link-type="uri" xlink:href="https://tcrex.biodatamining.be/">https://tcrex.biodatamining.be/</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">R</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org">https://www.r-project.org</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_001905">SCR_001905</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">RStudio</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://www.rstudio.com/">http://www.rstudio.com/</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_000432">SCR_000432</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ggplot2 (V3.3.2)</td><td align="left" valign="bottom">(<xref ref-type="bibr" rid="bib64">Wickham, 2016</xref>) <ext-link ext-link-type="uri" xlink:href="https://ggplot2.tidyverse.org/">https://ggplot2.tidyverse.org/</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014601">SCR_014601</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ggpubr (V0.2.5)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=ggpubr">https://CRAN.R-project.org/package=ggpubr</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_021139">SCR_021139</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">rstatix (0.7.0)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=rstatix">https://CRAN.R-project.org/package=rstatix</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_021240">SCR_021240</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Sytox blue</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# S34857</td><td align="left" valign="bottom">FACS (1/500 per test)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Fixable viability dye Zombie NIR</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 423106</td><td align="left" valign="bottom">FACS (1/50 per test)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Carboxyfluorescein succinimidyl ester (CFSE)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# C34554</td><td align="left" valign="bottom">2 µM staining solution</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Engerix-B</td><td align="left" valign="bottom">GlaxoSmithKline</td><td align="left" valign="bottom"/><td align="left" valign="bottom">20 μg</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Varicella zoster virus (VZV) lysate</td><td align="left" valign="bottom">Microbix Biosystem</td><td align="left" valign="bottom">Cat# EL-03–02</td><td align="left" valign="bottom">Viral lysate, assay (4 µg/ml)</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Human study design and clinical samples</title><p>A total of 34 healthy individuals (20-29 years: 10, 30-39 years: 7, 40-49 years: 16, 50+ years: 1) without a history of HBV infection or previous HB vaccination were recruited in this study after obtaining written informed consent. Individuals were vaccinated with an HB vaccine by intramuscular (m. deltoideus) injection (Engerix-B containing 20 μg dose of alum-adjuvanted HBsAg, GlaxoSmithKline) on days 0 and 30 (and on day 365). At days 0 (pre-vaccination), 60, 180, and 365 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), peripheral blood samples were collected on spray-coated lithium heparin tubes, spray-coated K2EDTA (dipotassium ethylenediamine tetra-acetic acid) tubes, and serum tubes (Becton Dickinson, NJ).</p></sec><sec id="s4-2"><title>Peripheral blood mononuclear cells</title><p>Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque Plus gradient separation (GE Healthcare, Chicago, IL). Cells were stored in 10% dimethyl sulfoxide in fetal bovine serum (Thermo Fisher Scientific, Waltham, MA). After thawing and washing cryopreserved PBMC, cells were cultured in AIM-V medium that contained L-glutamine, streptomycin sulfate at 50 µg/ml, and gentamicin sulfate at 10 µg/ml (Thermo Fisher Scientific, Waltham, MA) and supplemented with 5% human serum (One Lambda, Canoga Park, CA).</p></sec><sec id="s4-3"><title>Serology and complete blood count</title><p>Serum was separated and stored immediately at – 80°C until time of analysis. Anti-HBs antibody was titrated in serum from day 0, 60, 180, and 365 using Roche Elecsys Anti-HBs antibody assay on an Elecsys 2010 analyzer (Roche, Basel, Switzerland). An anti-HBs titer above 10 IU/ml was considered protective (<xref ref-type="bibr" rid="bib29">Keating and Noble, 2003</xref>).</p><p>Serum IgG antibodies to CMV, EBV viral-capsid antigen, and HSV-1 and -2 were determined using commercially available sandwich ELISA kits in accordance with the manufacturer’s instructions.</p><p>A complete blood count including leukocyte differential was run on a hematology analyzer (ABX MICROS 60, Horiba, Kyoto, Japan).</p></sec><sec id="s4-4"><title>Sorting of memory CD4 T cells</title><p>Total CD4 T cells were isolated by positive selection using CD4 magnetic microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany). Memory CD4 T cells were sorted after gating on single viable CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>−</sup>CD45RO<sup>+</sup> cells. The following fluorochrome-labeled monoclonal antibodies were used for staining: CD3-PerCP (BW264/56) (Miltenyi Biotech), CD4-APC (RPA-T4), and CD45RO-PE (UCHT1) (both from Becton Dickinson, Franklin Lakes, NJ) and CD8-Pacific Orange (3B5) (from Thermo Fisher Scientific, Waltham, MA). Cells were stained at room temperature for 20 min and sorted with FACSAria II (Becton Dickinson, Franklin Lakes, NJ). Sytox blue (Thermo Fisher Scientific, Waltham, MA) was used to exclude non-viable cells.</p></sec><sec id="s4-5"><title>Single peptides, peptide matrix pools, and epitope mapping</title><p>A set of 15-mers peptides with an 11-amino acid overlap spanning the 226 amino acids along the small S protein of HBsAg, also designated as small HBs (<xref ref-type="bibr" rid="bib59">Shouval, 2003</xref>), were synthesized by JPT Peptide Technologies (Berlin, Germany). The set, composed of 54 <bold>single peptides</bold> (see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), was used in a matrix-based strategy to map epitopes against which the immune response is directed as described before (<xref ref-type="bibr" rid="bib47">Precopio et al., 2008</xref>). The matrix layout enables efficient identification of epitopes within the antigen using a minimal number of cells. For this purpose, a matrix of 15 pools, 7 rows, and 8 columns, referred to as <bold>peptide matrix</bold>, was designed so that each peptide is in exactly one row-pool and one column-pool, thereby allowing for the identification of positive peptides at the intersection of positive pools. Matrix pools that induced a CD4 T cell response (as determined by CD40L/CD154 assay described below) which meets the threshold criteria for a positive response were considered in the deconvolution process. Top six single peptides were considered for peptide-specific T cell expansion and sorting. A <bold>master peptide pool</bold> is composed of all of the 54 single peptides and was used to identify and sort total vaccine-specific CD4 T cells. Each peptide was used at a final concentration of 2 µg/ml. VZV lysate was purchased from Microbix Biosystem (Mississauga, Canada).</p></sec><sec id="s4-6"><title>Ex vivo T cell stimulation (CD40L/CD154 assay)</title><p>Thawed PBMCs from each vaccinee were cultured in AIM-V medium that contained L-glutamine, streptomycin sulfate at 50 µg/ml, and gentamicin sulfate at 10 µg/ml (GIBCO, Grand Island, NY) and supplemented with 5% human serum (One Lambda, Canoga Park, CA). Cells were stimulated for 6 hr with 2 μg/ml of each of the 15 peptide matrix pools in the presence of 1 µg/ml anti-CD40 antibody (HB14) (purchased from Miltenyi Biotec, Bergisch Gladbach, Germany) and 1 μg/ml anti-CD28 antibody (CD28.2) (purchased from BD Biosciences, Franklin Lakes, NJ).</p><p>Cells were stained using the following fluorochrome-labeled monoclonal antibodies: CD3-PerCP (BW264/56), CD4-APC (REA623), CD8-VioGreen (REA734), and CD40L-PE (5C8) (purchased from Miltenyi Biotec, Bergisch Gladbach, Germany). Viability dye Sytox blue from Invitrogen (Thermo Fisher Scientific, Waltham, MA) was used to exclude non-viable cells. Data was acquired on FACSAria II using Diva Software, both from BD Biosciences (Franklin Lakes, NJ), and analyzed on FlowJo software version 10.5.3 (Tree Star, Inc, Ashland, OR). Fluorescence-minus-one controls were performed in pilot studies. Gates for CD40L<sup>+</sup>CD4 T cells were set using cells left unstimulated.</p></sec><sec id="s4-7"><title>In vitro T cell expansion and cell sorting</title><p>Thawed PBMCs were labeled with CFSE (Invitrogen, Carlsbad, CA) and cultured in AIM-V medium that contained L-glutamine, streptomycin sulfate at 50 µg/ml, and gentamicin sulfate at 10 µg/ml (GIBCO, Grand Island, NY) and supplemented with 5% human serum (One Lambda, Canoga Park, CA). Cells were stimulated for 7 days with 2 µg/ml of selected single peptides in addition to the master peptides pool. Cells were also stimulated with 4 µg/ml of a VZV lysate and used as a baseline control. Cells were stained using the following fluorochrome-labeled monoclonal antibodies: CD3-PerCP (BW264/56), CD4-APC (REA623), and CD8-VioGreen (REA734) (purchased from Miltenyi Biotec, Bergisch Gladbach, Germany). Viability dye Sytox blue from Invitrogen (Thermo Fisher Scientific, Waltham, MA) was used to exclude non-viable cells. Single viable CFSE<sup>low</sup> CD3<sup>+</sup> CD8<sup>−</sup> CD4<sup>+</sup> T cells were sorted into 96-well PCR plates containing DNA/RNA Shield (Zymo Research, Irvine, CA) using FACSAria II and Diva Software (BD Biosciences, Franklin Lakes, NJ). For each of the selected single peptides, 500 cells were sorted in two technical replicates. For the master peptide pool and VZV lysate, 1000 cells were sorted in two technical replicates. Plates were immediately centrifuged and kept at –20°C before TCR cDNA library preparation and sequencing.</p></sec><sec id="s4-8"><title>TCRβ cDNA library preparation and sequencing of memory CD4 T cells</title><p>DNA was extracted from sorted memory CD4 T cells using Quick-DNA Microprep kit (Zymo Research, Irvine, CA). ImmunoSEQ hsTCRB sequencing kit (Adaptive Biotechnologies, Seattle, WA) was used to profile TCRβ repertoire following the manufacturer’s protocol.</p><p>After quality control using Fragment Analyzer (Agilent, Santa Clara, CA), libraries were pooled with equal volumes. The concentration of the final pool was measured with the Qubit dsDNA HS Assay kit (Thermo Fisher Scientific, Waltham, MA). The final pool was processed to be sequenced on the Miseq and NextSeq platforms (Illumina, San Diego, CA). Memory CD4 T cells of one of the vaccinees (H42, a non-converter) was not sequenced due to a capacity issue.</p></sec><sec id="s4-9"><title>TCR cDNA library preparation and sequencing of CFSE<sup>low</sup> CD4 T cells</title><p>RNA was extracted from each of the two technical replicates of sorted CFSE<sup>low</sup> CD4 T cells using Quick-RNA Microprep kit (Zymo Research, Irvine, CA). Without measuring the resulting RNA concentration, an RNA-based library preparation was used. The QIAseq Immune Repertoire RNA Library kit (Qiagen, Venlo, The Netherlands) amplifies TCRα, -β, -γ, and -δ chains. After quality control using Fragment Analyzer (Agilent, Santa Clara, CA), concentration was measured with the Qubit dsDNA HS Assay kit (Thermo Fisher Scientific, Waltham, MA) and pools were equimolarly pooled and prepared for sequencing on the NextSeq platform (Illumina, San Diego, CA).</p></sec><sec id="s4-10"><title>TCRβ sequence analysis</title><p>TCRβ clonotypes were identified as previously described (<xref ref-type="bibr" rid="bib14">De Neuter et al., 2019</xref>) where a unique TCRβ clonotype is defined as a unique combination of a V gene, CDR3 amino acid sequence, and J gene. All memory CD4 T cell DNA-based TCRβ sequencing reads were annotated using the immunoSEQ analyzer (v2) from Adaptive Biotechnologies. All small bulk RNA-based TCR sequencing reads were annotated using the MiXCR tool (v3.0.7) from the FASTQ files. As all RNA-based TCR sequencing experiments featured two technical replicates, only those TCR sequences that occurred in both replicates were retained and their counts were summed. Tracking of vaccine-specific TCRβ clonotypes is based on exact TCRβ CDR3 amino acid matches to remove any bias introduced by the different VDJ annotation pipelines. Non-HBsAg TCR annotations were done with the TCRex web tool (<xref ref-type="bibr" rid="bib26">Gielis et al., 2019</xref>) on the July 24, 2019, using version 0.3.0. Breadth of the TCR sequences is defined as the number of unique TCR clonotypes belonging to a given set, divided by the total number of unique clonotypes in a repertoire. Inference of similar epitope binding between two TCR sequences is defined according to the Hamming distance (<italic>d</italic>) calculated on the CDR3 amino acid sequence with a cutoff <italic>c =</italic> 1, as supported by prior research where it was shown that it was equivalent to the performance of more complex methods such as TCRdist (<xref ref-type="bibr" rid="bib12">Dash et al., 2017</xref>) or k-mer clustering when applied to TCRβ chains only (<xref ref-type="bibr" rid="bib13">De Neuter et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Valkiers et al., 2021</xref>). All scripts used in this analysis are available via GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/pmeysman/HepBTCR">https://github.com/pmeysman/HepBTCR</ext-link>, copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:ba259d42b72b464259463236c4d69d7fdaba5d6f;origin=https://github.com/pmeysman/HepBTCR;visit=swh:1:snp:9af24b74d71fc0603e410d162ef528d4e4a2a6ff;anchor=swh:1:rev:bdda21dde671ac2e424e85bd270efafa719d4cb4">swh:1:rev:bdda21dde671ac2e424e85bd270efafa719d4cb4</ext-link>, <xref ref-type="bibr" rid="bib42">Meysman, 2022</xref>).</p></sec><sec id="s4-11"><title>Predictive HBs-response model</title><p>From the single peptide data generated in the epitope mapping experiments, we aimed to create a predictive model to enumerate the HBs response from full TCRβ repertoire data. This approach allows for predictions that are epitope-specific rather than simply vaccine-specific. This model was applied in a leave-one-out cross-validation so that vaccine-specific TCRβ sequences from a vaccinee are not used to make predictions for the same vaccinee. While the predictive model is derived from epitope-specific data, it cannot be guaranteed that some of the expanded CD4 T cells detected in the in vitro assay are not due to bystander activation. Vaccine-specific TCRβ sequences of vaccinees who did not respond to the vaccine at day 60 (late-converters and non-converters) are expected to be more enriched in cells triggered to expand due to bystander activation. Indeed, running the set of vaccine-specific TCRβ sequences through the TCRex webtool (<xref ref-type="bibr" rid="bib26">Gielis et al., 2019</xref>) reveals that several TCRs are predicted to be highly similar to those reactive to the CMV NLVPMVATV epitope (enrichment p-value &lt; 0.001 when compared to the TCRex background repertoire) and the Mart-1 variant ELAGIGILTV epitope (p-value &lt; 0.001), which supports the notion that some of these TCRβ sequences might not be specific to HBsAg. This set of vaccine-specific TCRβ sequences can thus be used to make predictions about possible TCRβ sequences due to bystander activation of CD4 T cells, that is, common TCRβ sequences that might be present as false positives. The final output of the model is thus a ratio, <italic>R<sub>hbs</sub></italic>, for any repertoire <italic>rep<sub>i</sub></italic> describing a set of TCRβ sequences <italic>t<sub>repi</sub></italic>:<disp-formula id="equ1"><mml:math id="m1"><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">h</mml:mi><mml:mi mathvariant="bold-italic">b</mml:mi><mml:mi mathvariant="bold-italic">s</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">r</mml:mi><mml:mi mathvariant="bold-italic">e</mml:mi><mml:mi mathvariant="bold-italic">p</mml:mi><mml:mi mathvariant="bold-italic">i</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mi mathvariant="bold-italic"> </mml:mi><mml:mfrac><mml:mrow><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi mathvariant="bold-italic">p</mml:mi><mml:mi mathvariant="bold-italic">e</mml:mi><mml:mi mathvariant="bold-italic">p</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>54</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:mfenced close="|" open="|" separators="|"><mml:mrow><mml:mfenced close="}" open="{" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mi mathvariant="bold-italic"> </mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="bold-italic"> </mml:mi><mml:mi mathvariant="bold-italic">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">r</mml:mi><mml:mi mathvariant="bold-italic">e</mml:mi><mml:mi mathvariant="bold-italic">p</mml:mi><mml:mi mathvariant="bold-italic">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">m</mml:mi><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mi mathvariant="bold-italic">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mi mathvariant="bold-italic"> </mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">p</mml:mi><mml:mi mathvariant="bold-italic">e</mml:mi><mml:mi mathvariant="bold-italic">p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mi mathvariant="bold-italic"> </mml:mi><mml:mi mathvariant="bold-italic">d</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow></mml:mfenced><mml:mo>§amp;lt;</mml:mo><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:mfenced close="|" open="|" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">p</mml:mi><mml:mi mathvariant="bold-italic">e</mml:mi><mml:mi mathvariant="bold-italic">p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mi mathvariant="bold-italic"> </mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mfenced close="|" open="|" separators="|"><mml:mrow><mml:mfenced close="}" open="{" separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mi mathvariant="bold-italic"> </mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">r</mml:mi><mml:mi mathvariant="bold-italic">e</mml:mi><mml:mi mathvariant="bold-italic">p</mml:mi><mml:mi mathvariant="bold-italic">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">m</mml:mi><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mi mathvariant="bold-italic">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mi mathvariant="bold-italic"> </mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">b</mml:mi><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mi mathvariant="bold-italic">s</mml:mi><mml:mi mathvariant="bold-italic">t</mml:mi><mml:mi mathvariant="bold-italic">a</mml:mi><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mi mathvariant="bold-italic">d</mml:mi><mml:mi mathvariant="bold-italic">e</mml:mi><mml:mi mathvariant="bold-italic">r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mi mathvariant="bold-italic"> </mml:mi><mml:mi mathvariant="bold-italic">d</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow></mml:mfenced><mml:mo>§amp;lt;</mml:mo><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:mfenced close="|" open="|" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">b</mml:mi><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mi mathvariant="bold-italic">s</mml:mi><mml:mi mathvariant="bold-italic">t</mml:mi><mml:mi mathvariant="bold-italic">a</mml:mi><mml:mi mathvariant="bold-italic">n</mml:mi><mml:mi mathvariant="bold-italic">d</mml:mi><mml:mi mathvariant="bold-italic">e</mml:mi><mml:mi mathvariant="bold-italic">r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>with <italic>t<sub>pep</sub></italic> as the set of TCRβ sequences occurring in both biological replicates for a single sample and a single peptide (<italic>pep</italic>) from the HBsAg epitope mapping experiment, and <italic>t<sub>bystander</sub></italic> as the set of TCRβ sequences occurring in both biological replicates of the master peptide pool in any of the non-responding samples. Thus, the ratio signifies the number of TCR clonotypes predicted to be reactive against one of the HBsAg peptides, normalized by a count of putative false positive predictions from bystander T cells.</p></sec><sec id="s4-12"><title>Ex vivo T cell phenotyping of vaccine-specific T cells</title><p>Thawed PBMCs from each vaccinee were cultured in AIM-V medium that contained L-glutamine, streptomycin sulfate at 50 µg/ml, and gentamicin sulfate at 10 µg/ml (GIBCO, Grand Island, NY) and supplemented with 5% human serum (One Lambda, Canoga Park, CA). Cells were stimulated for 6 hr with 2 μg/ml of a master peptide pool representing the full length of the small surface envelope protein of HB, in the presence of 1 µg/ml anti-CD40 antibody (HB14) (purchased from Miltenyi Biotec, Bergisch Gladbach, Germany) and 1 μg/ml anti-CD28 antibody (CD28.2) (purchased from BD Biosciences, Franklin Lakes, NJ). Cells were stained using the following fluorochrome-labeled monoclonal antibodies: CD3-BV510 (SK7), CD4-PerCP/Cy5.5 (RPA-T4), CD8-APC/Cy7 (SK1), CD45RA-AF488 (HI100), CD25-BV421 (M-A251), CD127-BV785 (A019D5), and CD137-PE (4-1BB) (purchased from BioLegend, San Diego, CA), CXCR5 (CD185)-PE-eFluor 610 (MU5UBEE) (from eBioscience, Thermo Fisher Scientific, Waltham, MA) and CD40L-APC (5C8) (purchased from Miltenyi Biotec, Bergisch Gladbach, Germany). Fixable viability dye Zombie NIR from BioLegend (San Diego, CA) was used to exclude non-viable cells. Data was acquired on FACSAria II using Diva Software, both from BD Biosciences (Franklin Lakes, NJ), and analyzed on FlowJo software version 10.5.3 (Tree Star, Inc, Ashland, OR) using gating strategy shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>. Fluorescence-minus-one controls were performed in pilot studies. Gates for CD40L<sup>+</sup> and 4-1BB<sup>+</sup> CD4 T cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>) were set using cells left unstimulated (negative control contained DMSO at the same concentration used to solve peptide pools). In order to account for background expression of CD40L and 4-1BB on CD4 T cells, responses in cells left unstimulated were subtracted from the responses to peptides, and when peptides-specific CD40L<sup>+</sup> or 4-1BB<sup>+</sup> CD4 T cells were not significantly higher than those detected for cells left unstimulated (using one-sided Fisher’s exact test), values were mutated to zero.</p></sec><sec id="s4-13"><title>Statistics and data visualization</title><p>The two-sided Fisher’s exact test was used to evaluate the significance of relationship between early/late-converters and CMV, EBV, or HSV seropositivity. For the visualization of marker expression, TCRβ counts and cell frequencies between time points or groups of vaccinees, ggplot2 (v3.3.2), ggpubr (v0.2.5), and rstatix (v0.7.0) packages in R were used. The Wilcoxon rank sum test and the Wilcoxon signed-rank test were used to compare two or more groups, with unpaired and paired analysis as necessary. Bonferroni correction was applied when multiple comparisons were made. The nonparametric Spearman’s rank-order correlation was used to test for correlation. We used the following convention for symbols indicating statistical significance; ns p &gt; 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Investigation, Methodology, Software, Visualization, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Supervision, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Funding acquisition, Methodology, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Project administration, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Project administration, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Data curation, Funding acquisition, Project administration</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Funding acquisition, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study was approved by the Ethics Committee of the Antwerp University Hospital and University of Antwerp, Belgium (IRB 15/19/210). Written informed consent and consent to publish were obtained from all study participants. All experiments and methods were performed in accordance with the relevant guidelines and regulations when applicable.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>List of 54 single peptides, each 15 amino acid (AA) long with an 11-AA overlap spanning the 226 AAs along the small S protein of hepatitis B (HB) surface antigen (HBsAg).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68388-supp1-v3.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Overview of the single peptides tested for each vaccinee in the carboxyfluorescein succinimidyl ester (CFSE) assay.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68388-supp2-v3.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-68388-transrepform1-v3.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>The sequencing data that support the findings of this study have been deposited on Zenodo (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.3989144">https://doi.org/10.5281/zenodo.3989144</ext-link>). Flow Cytometry Standard (FCS) data files with associated FlowJo workspaces are deposited at <ext-link ext-link-type="uri" xlink:href="http://flowrepository.org/">flowrepository.org</ext-link> under the following experiment names: epitope mapping: <ext-link ext-link-type="uri" xlink:href="https://flowrepository.org/id/FR-FCM-Z2TN">https://flowrepository.org/id/FR-FCM-Z2TN</ext-link>; in vitro T cell expansion: <ext-link ext-link-type="uri" xlink:href="https://flowrepository.org/id/FR-FCM-Z2TM">https://flowrepository.org/id/FR-FCM-Z2TM</ext-link>; ex vivo CD4 T cell assay: <ext-link ext-link-type="uri" xlink:href="https://flowrepository.org/id/FR-FCM-Z2TL">https://flowrepository.org/id/FR-FCM-Z2TL</ext-link>.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Meysman</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon vaccination</data-title><source>Zenodo</source><pub-id pub-id-type="doi">10.5281/zenodo.3989144</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>In vitro T cell expansion</data-title><source>flowrepository</source><pub-id pub-id-type="accession" xlink:href="https://flowrepository.org/id/FR-FCM-Z2TM">FR-FCM-Z2TM</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>ex vivo CD4 T cell assay</data-title><source>flowrepository</source><pub-id pub-id-type="accession" xlink:href="https://flowrepository.org/id/FR-FCM-Z2TL">FR-FCM-Z2TL</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Epitope mapping</data-title><source>flowrepository</source><pub-id pub-id-type="accession" xlink:href="https://flowrepository.org/id/FR-FCM-Z2TN">FR-FCM-Z2TN</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank all the volunteers in the study, and all the nurses, lab technicians, researchers, and staff in the clinical biology laboratory of Antwerp University Hospital and the Centre for the Evaluation of Vaccination at the Vaccine and Infectious Disease Institute that were involved in the study. In addition, we wish to thank Nick de Vrij and Sebastiaan Valkiers for critically reading the manuscript for clarity. We further thank the reviewers and editors for their many suggestions that helped improve this work.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacher</surname><given-names>P</given-names></name><name><surname>Schink</surname><given-names>C</given-names></name><name><surname>Teutschbein</surname><given-names>J</given-names></name><name><surname>Kniemeyer</surname><given-names>O</given-names></name><name><surname>Assenmacher</surname><given-names>M</given-names></name><name><surname>Brakhage</surname><given-names>AA</given-names></name><name><surname>Scheffold</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive and memory Th cell repertoire</article-title><source>Journal of Immunology</source><volume>190</volume><fpage>3967</fpage><lpage>3976</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202221</pub-id><pub-id pub-id-type="pmid">23479226</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacher</surname><given-names>P</given-names></name><name><surname>Kniemeyer</surname><given-names>O</given-names></name><name><surname>Teutschbein</surname><given-names>J</given-names></name><name><surname>Thön</surname><given-names>M</given-names></name><name><surname>Vödisch</surname><given-names>M</given-names></name><name><surname>Wartenberg</surname><given-names>D</given-names></name><name><surname>Scharf</surname><given-names>DH</given-names></name><name><surname>Koester-Eiserfunke</surname><given-names>N</given-names></name><name><surname>Schütte</surname><given-names>M</given-names></name><name><surname>Dübel</surname><given-names>S</given-names></name><name><surname>Assenmacher</surname><given-names>M</given-names></name><name><surname>Brakhage</surname><given-names>AA</given-names></name><name><surname>Scheffold</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014a</year><article-title>Identification of immunogenic antigens from Aspergillus fumigatus by direct multiparameter characterization of specific conventional and regulatory CD4+ T cells</article-title><source>Journal of Immunology</source><volume>193</volume><fpage>3332</fpage><lpage>3343</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1400776</pub-id><pub-id pub-id-type="pmid">25172488</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacher</surname><given-names>P</given-names></name><name><surname>Kniemeyer</surname><given-names>O</given-names></name><name><surname>Schönbrunn</surname><given-names>A</given-names></name><name><surname>Sawitzki</surname><given-names>B</given-names></name><name><surname>Assenmacher</surname><given-names>M</given-names></name><name><surname>Rietschel</surname><given-names>E</given-names></name><name><surname>Steinbach</surname><given-names>A</given-names></name><name><surname>Cornely</surname><given-names>OA</given-names></name><name><surname>Brakhage</surname><given-names>AA</given-names></name><name><surname>Thiel</surname><given-names>A</given-names></name><name><surname>Scheffold</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014b</year><article-title>Antigen-specific expansion of human regulatory T cells as a major tolerance mechanism against mucosal fungi</article-title><source>Mucosal Immunology</source><volume>7</volume><fpage>916</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1038/mi.2013.107</pub-id><pub-id pub-id-type="pmid">24301658</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becattini</surname><given-names>S</given-names></name><name><surname>Latorre</surname><given-names>D</given-names></name><name><surname>Mele</surname><given-names>F</given-names></name><name><surname>Foglierini</surname><given-names>M</given-names></name><name><surname>De Gregorio</surname><given-names>C</given-names></name><name><surname>Cassotta</surname><given-names>A</given-names></name><name><surname>Fernandez</surname><given-names>B</given-names></name><name><surname>Kelderman</surname><given-names>S</given-names></name><name><surname>Schumacher</surname><given-names>TN</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>T cell clones primed by pathogens or vaccines</article-title><source>Science</source><volume>347</volume><fpage>400</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1126/science.1260668</pub-id><pub-id pub-id-type="pmid">25477212</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bentebibel</surname><given-names>SE</given-names></name><name><surname>Schmitt</surname><given-names>N</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Ueno</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Human tonsil B-cell lymphoma 6 (BCL6)-expressing CD4+ T-cell subset specialized for B-cell help outside germinal centers</article-title><source>PNAS</source><volume>108</volume><fpage>E488</fpage><lpage>E497</lpage><pub-id pub-id-type="doi">10.1073/pnas.1100898108</pub-id><pub-id pub-id-type="pmid">21808017</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blom</surname><given-names>K</given-names></name><name><surname>Braun</surname><given-names>M</given-names></name><name><surname>Ivarsson</surname><given-names>MA</given-names></name><name><surname>Gonzalez</surname><given-names>VD</given-names></name><name><surname>Falconer</surname><given-names>K</given-names></name><name><surname>Moll</surname><given-names>M</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name><name><surname>Michaëlsson</surname><given-names>J</given-names></name><name><surname>Sandberg</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response</article-title><source>Journal of Immunology</source><volume>190</volume><fpage>2150</fpage><lpage>2158</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202234</pub-id><pub-id pub-id-type="pmid">23338234</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>NJ</given-names></name><name><surname>McQuaid</surname><given-names>AJ</given-names></name><name><surname>Sobande</surname><given-names>T</given-names></name><name><surname>Kissane</surname><given-names>S</given-names></name><name><surname>Agius</surname><given-names>E</given-names></name><name><surname>Jackson</surname><given-names>SE</given-names></name><name><surname>Salmon</surname><given-names>M</given-names></name><name><surname>Falciani</surname><given-names>F</given-names></name><name><surname>Yong</surname><given-names>K</given-names></name><name><surname>Rustin</surname><given-names>MH</given-names></name><name><surname>Akbar</surname><given-names>AN</given-names></name><name><surname>Vukmanovic-Stejic</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO</article-title><source>Journal of Immunology</source><volume>184</volume><fpage>4317</fpage><lpage>4326</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903781</pub-id><pub-id pub-id-type="pmid">20231690</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brezar</surname><given-names>V</given-names></name><name><surname>Godot</surname><given-names>V</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Lévy</surname><given-names>Y</given-names></name><name><surname>Seddiki</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>T-Regulatory Cells and Vaccination “Pay Attention and Do Not Neglect Them”: Lessons from HIV and Cancer Vaccine Trials</article-title><source>Vaccines</source><volume>4</volume><elocation-id>E30</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines4030030</pub-id><pub-id pub-id-type="pmid">27608046</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campion</surname><given-names>SL</given-names></name><name><surname>Brodie</surname><given-names>TM</given-names></name><name><surname>Fischer</surname><given-names>W</given-names></name><name><surname>Korber</surname><given-names>BT</given-names></name><name><surname>Rossetti</surname><given-names>A</given-names></name><name><surname>Goonetilleke</surname><given-names>N</given-names></name><name><surname>McMichael</surname><given-names>AJ</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Proteome-wide analysis of HIV-specific naive and memory CD4(+) T cells in unexposed blood donors</article-title><source>The Journal of Experimental Medicine</source><volume>211</volume><fpage>1273</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1084/jem.20130555</pub-id><pub-id pub-id-type="pmid">24958850</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>HH</given-names></name><name><surname>Chien</surname><given-names>WH</given-names></name><name><surname>Wu</surname><given-names>LL</given-names></name><name><surname>Cheng</surname><given-names>CH</given-names></name><name><surname>Chung</surname><given-names>CH</given-names></name><name><surname>Horng</surname><given-names>JH</given-names></name><name><surname>Ni</surname><given-names>YH</given-names></name><name><surname>Tseng</surname><given-names>HT</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Chen</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota</article-title><source>PNAS</source><volume>112</volume><fpage>2175</fpage><lpage>2180</lpage><pub-id pub-id-type="doi">10.1073/pnas.1424775112</pub-id><pub-id pub-id-type="pmid">25646429</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtsinger</surname><given-names>JM</given-names></name><name><surname>Mescher</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Inflammatory cytokines as a third signal for T cell activation</article-title><source>Current Opinion in Immunology</source><volume>22</volume><fpage>333</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2010.02.013</pub-id><pub-id pub-id-type="pmid">20363604</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dash</surname><given-names>P</given-names></name><name><surname>Fiore-Gartland</surname><given-names>AJ</given-names></name><name><surname>Hertz</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>GC</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Souquette</surname><given-names>A</given-names></name><name><surname>Crawford</surname><given-names>JC</given-names></name><name><surname>Clemens</surname><given-names>EB</given-names></name><name><surname>Nguyen</surname><given-names>THO</given-names></name><name><surname>Kedzierska</surname><given-names>K</given-names></name><name><surname>La Gruta</surname><given-names>NL</given-names></name><name><surname>Bradley</surname><given-names>P</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Quantifiable predictive features define epitope-specific T cell receptor repertoires</article-title><source>Nature</source><volume>547</volume><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/nature22383</pub-id><pub-id pub-id-type="pmid">28636592</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Neuter</surname><given-names>N</given-names></name><name><surname>Bittremieux</surname><given-names>W</given-names></name><name><surname>Beirnaert</surname><given-names>C</given-names></name><name><surname>Cuypers</surname><given-names>B</given-names></name><name><surname>Mrzic</surname><given-names>A</given-names></name><name><surname>Moris</surname><given-names>P</given-names></name><name><surname>Suls</surname><given-names>A</given-names></name><name><surname>Van Tendeloo</surname><given-names>V</given-names></name><name><surname>Ogunjimi</surname><given-names>B</given-names></name><name><surname>Laukens</surname><given-names>K</given-names></name><name><surname>Meysman</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>On the feasibility of mining CD8+ T cell receptor patterns underlying immunogenic peptide recognition</article-title><source>Immunogenetics</source><volume>70</volume><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1007/s00251-017-1023-5</pub-id><pub-id pub-id-type="pmid">28779185</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Neuter</surname><given-names>N</given-names></name><name><surname>Bartholomeus</surname><given-names>E</given-names></name><name><surname>Elias</surname><given-names>G</given-names></name><name><surname>Keersmaekers</surname><given-names>N</given-names></name><name><surname>Suls</surname><given-names>A</given-names></name><name><surname>Jansens</surname><given-names>H</given-names></name><name><surname>Smits</surname><given-names>E</given-names></name><name><surname>Hens</surname><given-names>N</given-names></name><name><surname>Beutels</surname><given-names>P</given-names></name><name><surname>Van Damme</surname><given-names>P</given-names></name><name><surname>Mortier</surname><given-names>G</given-names></name><name><surname>Van Tendeloo</surname><given-names>V</given-names></name><name><surname>Laukens</surname><given-names>K</given-names></name><name><surname>Meysman</surname><given-names>P</given-names></name><name><surname>Ogunjimi</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Memory CD4T cell receptor repertoire data mining as a tool for identifying cytomegalovirus serostatus</article-title><source>Genes and Immunity</source><volume>20</volume><fpage>255</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1038/s41435-018-0035-y</pub-id><pub-id pub-id-type="pmid">29904098</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeWitt</surname><given-names>WS</given-names></name><name><surname>Emerson</surname><given-names>RO</given-names></name><name><surname>Lindau</surname><given-names>P</given-names></name><name><surname>Vignali</surname><given-names>M</given-names></name><name><surname>Snyder</surname><given-names>TM</given-names></name><name><surname>Desmarais</surname><given-names>C</given-names></name><name><surname>Sanders</surname><given-names>C</given-names></name><name><surname>Utsugi</surname><given-names>H</given-names></name><name><surname>Warren</surname><given-names>EH</given-names></name><name><surname>McElrath</surname><given-names>J</given-names></name><name><surname>Makar</surname><given-names>KW</given-names></name><name><surname>Wald</surname><given-names>A</given-names></name><name><surname>Robins</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dynamics of the cytotoxic T cell response to a model of acute viral infection</article-title><source>Journal of Virology</source><volume>89</volume><fpage>4517</fpage><lpage>4526</lpage><pub-id pub-id-type="doi">10.1128/JVI.03474-14</pub-id><pub-id pub-id-type="pmid">25653453</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeWitt</surname><given-names>WS</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Schoch</surname><given-names>G</given-names></name><name><surname>Hansen</surname><given-names>JA</given-names></name><name><surname>Matsen</surname><given-names>FA</given-names></name><name><surname>Bradley</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Human T cell receptor occurrence patterns encode immune history, genetic background, and receptor specificity</article-title><source>eLife</source><volume>7</volume><elocation-id>e38358</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.38358</pub-id><pub-id pub-id-type="pmid">30152754</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>G</given-names></name><name><surname>Ogunjimi</surname><given-names>B</given-names></name><name><surname>Van Tendeloo</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Activation-induced surface proteins in the identification of antigen-responsive CD4 T cells</article-title><source>Immunology Letters</source><volume>219</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2019.12.006</pub-id><pub-id pub-id-type="pmid">31881234</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emerson</surname><given-names>RO</given-names></name><name><surname>DeWitt</surname><given-names>WS</given-names></name><name><surname>Vignali</surname><given-names>M</given-names></name><name><surname>Gravley</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>JK</given-names></name><name><surname>Osborne</surname><given-names>EJ</given-names></name><name><surname>Desmarais</surname><given-names>C</given-names></name><name><surname>Klinger</surname><given-names>M</given-names></name><name><surname>Carlson</surname><given-names>CS</given-names></name><name><surname>Hansen</surname><given-names>JA</given-names></name><name><surname>Rieder</surname><given-names>M</given-names></name><name><surname>Robins</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire</article-title><source>Nature Genetics</source><volume>49</volume><fpage>659</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1038/ng.3822</pub-id><pub-id pub-id-type="pmid">28369038</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esensten</surname><given-names>JH</given-names></name><name><surname>Helou</surname><given-names>YA</given-names></name><name><surname>Chopra</surname><given-names>G</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CD28 Costimulation: From Mechanism to Therapy</article-title><source>Immunity</source><volume>44</volume><fpage>973</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.04.020</pub-id><pub-id pub-id-type="pmid">27192564</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farber</surname><given-names>DL</given-names></name><name><surname>Yudanin</surname><given-names>NA</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Human memory T cells: generation, compartmentalization and homeostasis</article-title><source>Nature Reviews. Immunology</source><volume>14</volume><fpage>24</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1038/nri3567</pub-id><pub-id pub-id-type="pmid">24336101</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonseca</surname><given-names>VR</given-names></name><name><surname>Agua-Doce</surname><given-names>A</given-names></name><name><surname>Maceiras</surname><given-names>AR</given-names></name><name><surname>Pierson</surname><given-names>W</given-names></name><name><surname>Ribeiro</surname><given-names>F</given-names></name><name><surname>Romão</surname><given-names>VC</given-names></name><name><surname>Pires</surname><given-names>AR</given-names></name><name><surname>da Silva</surname><given-names>SL</given-names></name><name><surname>Fonseca</surname><given-names>JE</given-names></name><name><surname>Sousa</surname><given-names>AE</given-names></name><name><surname>Linterman</surname><given-names>MA</given-names></name><name><surname>Graca</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Human blood Tfr cells are indicators of ongoing humoral activity not fully licensed with suppressive function</article-title><source>Science Immunology</source><volume>2</volume><elocation-id>eaan1487</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aan1487</pub-id><pub-id pub-id-type="pmid">28802258</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frentsch</surname><given-names>M</given-names></name><name><surname>Arbach</surname><given-names>O</given-names></name><name><surname>Kirchhoff</surname><given-names>D</given-names></name><name><surname>Moewes</surname><given-names>B</given-names></name><name><surname>Worm</surname><given-names>M</given-names></name><name><surname>Rothe</surname><given-names>M</given-names></name><name><surname>Scheffold</surname><given-names>A</given-names></name><name><surname>Thiel</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Direct access to CD4+ T cells specific for defined antigens according to CD154 expression</article-title><source>Nature Medicine</source><volume>11</volume><fpage>1118</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1038/nm1292</pub-id><pub-id pub-id-type="pmid">16186818</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furman</surname><given-names>D</given-names></name><name><surname>Jojic</surname><given-names>V</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Shen-Orr</surname><given-names>SS</given-names></name><name><surname>L. Angel</surname><given-names>CJ</given-names></name><name><surname>Onengut-Gumuscu</surname><given-names>S</given-names></name><name><surname>Kidd</surname><given-names>BA</given-names></name><name><surname>Maecker</surname><given-names>HT</given-names></name><name><surname>Concannon</surname><given-names>P</given-names></name><name><surname>Dekker</surname><given-names>CL</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cytomegalovirus infection enhances the immune response to influenza</article-title><source>Science Translational Medicine</source><volume>7</volume><elocation-id>281ra43</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa2293</pub-id><pub-id pub-id-type="pmid">25834109</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galson</surname><given-names>JD</given-names></name><name><surname>Trück</surname><given-names>J</given-names></name><name><surname>Clutterbuck</surname><given-names>EA</given-names></name><name><surname>Fowler</surname><given-names>A</given-names></name><name><surname>Cerundolo</surname><given-names>V</given-names></name><name><surname>Pollard</surname><given-names>AJ</given-names></name><name><surname>Lunter</surname><given-names>G</given-names></name><name><surname>Kelly</surname><given-names>DF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>B-cell repertoire dynamics after sequential hepatitis B vaccination and evidence for cross-reactive B-cell activation</article-title><source>Genome Medicine</source><volume>8</volume><elocation-id>68</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-016-0322-z</pub-id><pub-id pub-id-type="pmid">27312086</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garner-Spitzer</surname><given-names>E</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Paulke-Korinek</surname><given-names>M</given-names></name><name><surname>Kollaritsch</surname><given-names>H</given-names></name><name><surname>Heinz</surname><given-names>FX</given-names></name><name><surname>Redlberger-Fritz</surname><given-names>M</given-names></name><name><surname>Stiasny</surname><given-names>K</given-names></name><name><surname>Fischer</surname><given-names>GF</given-names></name><name><surname>Kundi</surname><given-names>M</given-names></name><name><surname>Wiedermann</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Tick-Borne Encephalitis (TBE) and Hepatitis B Nonresponders Feature Different Immunologic Mechanisms in Response to TBE and Influenza Vaccination with Involvement of Regulatory T and B Cells and IL-10</article-title><source>The Journal of Immunology</source><volume>191</volume><fpage>2426</fpage><lpage>2436</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1300293</pub-id><pub-id pub-id-type="pmid">23872054</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gielis</surname><given-names>S</given-names></name><name><surname>Moris</surname><given-names>P</given-names></name><name><surname>Bittremieux</surname><given-names>W</given-names></name><name><surname>De Neuter</surname><given-names>N</given-names></name><name><surname>Ogunjimi</surname><given-names>B</given-names></name><name><surname>Laukens</surname><given-names>K</given-names></name><name><surname>Meysman</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Detection of Enriched T Cell Epitope Specificity in Full T Cell Receptor Sequence Repertoires</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>e2820</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.02820</pub-id><pub-id pub-id-type="pmid">31849987</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Hanabuchi</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>WR</given-names></name><name><surname>Arima</surname><given-names>K</given-names></name><name><surname>Bover</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>FXF</given-names></name><name><surname>Gilliet</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>YJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Two Functional Subsets of FOXP3+ Regulatory T Cells in Human Thymus and Periphery</article-title><source>Immunity</source><volume>28</volume><fpage>870</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.03.018</pub-id><pub-id pub-id-type="pmid">18513999</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachapati</surname><given-names>K</given-names></name><name><surname>Adams</surname><given-names>DE</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Steward</surname><given-names>CA</given-names></name><name><surname>Rainbow</surname><given-names>DB</given-names></name><name><surname>Wicker</surname><given-names>LS</given-names></name><name><surname>Mittler</surname><given-names>RS</given-names></name><name><surname>Ridgway</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The B10 Idd9.3 locus mediates accumulation of functionally superior CD137(+) regulatory T cells in the nonobese diabetic type 1 diabetes model</article-title><source>Journal of Immunology</source><volume>189</volume><fpage>5001</fpage><lpage>5015</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1101013</pub-id><pub-id pub-id-type="pmid">23066155</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keating</surname><given-names>GM</given-names></name><name><surname>Noble</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Recombinant Hepatitis B Vaccine (Engerix-B??)</article-title><source>Drugs</source><volume>63</volume><fpage>1021</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.2165/00003495-200363100-00006</pub-id><pub-id pub-id-type="pmid">12699402</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Choi</surname><given-names>BK</given-names></name><name><surname>Shin</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Oh</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>DG</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Vinay</surname><given-names>DS</given-names></name><name><surname>Kwon</surname><given-names>BS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>4-1BB triggering ameliorates experimental autoimmune encephalomyelitis by modulating the balance between Th17 and regulatory T cells</article-title><source>Journal of Immunology</source><volume>187</volume><fpage>1120</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1002681</pub-id><pub-id pub-id-type="pmid">21715692</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klarenbeek</surname><given-names>PL</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>van Schaik</surname><given-names>BDC</given-names></name><name><surname>Zwinderman</surname><given-names>AH</given-names></name><name><surname>Jakobs</surname><given-names>ME</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>van Kampen</surname><given-names>AHC</given-names></name><name><surname>van Lier</surname><given-names>RAW</given-names></name><name><surname>Baas</surname><given-names>F</given-names></name><name><surname>de Vries</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Human T-cell memory consists mainly of unexpanded clones</article-title><source>Immunology Letters</source><volume>133</volume><fpage>42</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2010.06.011</pub-id><pub-id pub-id-type="pmid">20621124</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohler</surname><given-names>S</given-names></name><name><surname>Bethke</surname><given-names>N</given-names></name><name><surname>Böthe</surname><given-names>M</given-names></name><name><surname>Sommerick</surname><given-names>S</given-names></name><name><surname>Frentsch</surname><given-names>M</given-names></name><name><surname>Romagnani</surname><given-names>C</given-names></name><name><surname>Niedrig</surname><given-names>M</given-names></name><name><surname>Thiel</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The early cellular signatures of protective immunity induced by live viral vaccination</article-title><source>European Journal of Immunology</source><volume>42</volume><fpage>2363</fpage><lpage>2373</lpage><pub-id pub-id-type="doi">10.1002/eji.201142306</pub-id><pub-id pub-id-type="pmid">22733156</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krangel</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mechanics of T cell receptor gene rearrangement</article-title><source>Current Opinion in Immunology</source><volume>21</volume><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2009.03.009</pub-id><pub-id pub-id-type="pmid">19362456</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanteri</surname><given-names>MC</given-names></name><name><surname>O’Brien</surname><given-names>KM</given-names></name><name><surname>Purtha</surname><given-names>WE</given-names></name><name><surname>Cameron</surname><given-names>MJ</given-names></name><name><surname>Lund</surname><given-names>JM</given-names></name><name><surname>Owen</surname><given-names>RE</given-names></name><name><surname>Heitman</surname><given-names>JW</given-names></name><name><surname>Custer</surname><given-names>B</given-names></name><name><surname>Hirschkorn</surname><given-names>DF</given-names></name><name><surname>Tobler</surname><given-names>LH</given-names></name><name><surname>Kiely</surname><given-names>N</given-names></name><name><surname>Prince</surname><given-names>HE</given-names></name><name><surname>Ndhlovu</surname><given-names>LC</given-names></name><name><surname>Nixon</surname><given-names>DF</given-names></name><name><surname>Kamel</surname><given-names>HT</given-names></name><name><surname>Kelvin</surname><given-names>DJ</given-names></name><name><surname>Busch</surname><given-names>MP</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Norris</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Tregs control the development of symptomatic West Nile virus infection in humans and mice</article-title><source>The Journal of Clinical Investigation</source><volume>119</volume><fpage>3266</fpage><lpage>3277</lpage><pub-id pub-id-type="doi">10.1172/JCI39387</pub-id><pub-id pub-id-type="pmid">19855131</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>PH</given-names></name><name><surname>Wong</surname><given-names>WI</given-names></name><name><surname>Wang</surname><given-names>YL</given-names></name><name><surname>Hsieh</surname><given-names>MP</given-names></name><name><surname>Lu</surname><given-names>CW</given-names></name><name><surname>Liang</surname><given-names>CY</given-names></name><name><surname>Jui</surname><given-names>SH</given-names></name><name><surname>Wu</surname><given-names>FY</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Yang</surname><given-names>HC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Vaccine-induced antigen-specific regulatory T cells attenuate the antiviral immunity against acute influenza virus infection</article-title><source>Mucosal Immunology</source><volume>11</volume><fpage>1239</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1038/s41385-018-0004-9</pub-id><pub-id pub-id-type="pmid">29467445</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Putnam</surname><given-names>AL</given-names></name><name><surname>Xu-Yu</surname><given-names>Z</given-names></name><name><surname>Szot</surname><given-names>GL</given-names></name><name><surname>Lee</surname><given-names>MR</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Gottlieb</surname><given-names>PA</given-names></name><name><surname>Kapranov</surname><given-names>P</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name><name><surname>Fazekas de St Groth</surname><given-names>B</given-names></name><name><surname>Clayberger</surname><given-names>C</given-names></name><name><surname>Soper</surname><given-names>DM</given-names></name><name><surname>Ziegler</surname><given-names>SF</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells</article-title><source>The Journal of Experimental Medicine</source><volume>203</volume><fpage>1701</fpage><lpage>1711</lpage><pub-id pub-id-type="doi">10.1084/jem.20060772</pub-id><pub-id pub-id-type="pmid">16818678</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovelace</surname><given-names>P</given-names></name><name><surname>Maecker</surname><given-names>HT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Multiparameter Intracellular Cytokine Staining</article-title><source>In Methods in Molecular Biology</source><volume>1</volume><fpage>151</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7346-0_9</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>GM</given-names></name><name><surname>Lowe</surname><given-names>K</given-names></name><name><surname>Melchiotti</surname><given-names>R</given-names></name><name><surname>Ellis</surname><given-names>R</given-names></name><name><surname>Rinaldis</surname><given-names>E</given-names></name><name><surname>Peakman</surname><given-names>M</given-names></name><name><surname>Heck</surname><given-names>S</given-names></name><name><surname>Lombardi</surname><given-names>G</given-names></name><name><surname>Tree</surname><given-names>TIM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Phenotypic Complexity of the Human Regulatory T</article-title><source>Cell Compartment Revealed by Mass Cytometry. J. Immunol</source><volume>195</volume><fpage>2030</fpage><lpage>2037</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1500703</pub-id><pub-id pub-id-type="pmid">26223658</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McHugh</surname><given-names>RS</given-names></name><name><surname>Whitters</surname><given-names>MJ</given-names></name><name><surname>Piccirillo</surname><given-names>CA</given-names></name><name><surname>Young</surname><given-names>DA</given-names></name><name><surname>Shevach</surname><given-names>EM</given-names></name><name><surname>Collins</surname><given-names>M</given-names></name><name><surname>Byrne</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor</article-title><source>Immunity</source><volume>16</volume><fpage>311</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(02)00280-7</pub-id><pub-id pub-id-type="pmid">11869690</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meireles</surname><given-names>LC</given-names></name><name><surname>Marinho</surname><given-names>RT</given-names></name><name><surname>Van Damme</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Three decades of hepatitis B control with vaccination</article-title><source>World Journal of Hepatology</source><volume>7</volume><fpage>2127</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.4254/wjh.v7.i18.2127</pub-id><pub-id pub-id-type="pmid">26328023</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meysman</surname><given-names>P</given-names></name><name><surname>De Neuter</surname><given-names>N</given-names></name><name><surname>Gielis</surname><given-names>S</given-names></name><name><surname>Bui Thi</surname><given-names>D</given-names></name><name><surname>Ogunjimi</surname><given-names>B</given-names></name><name><surname>Laukens</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>On the viability of unsupervised T-cell receptor sequence clustering for epitope preference</article-title><source>Bioinformatics</source><volume>35</volume><fpage>1461</fpage><lpage>1468</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty821</pub-id><pub-id pub-id-type="pmid">30247624</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Meysman</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon vaccination</data-title><version designator="swh:1:rev:bdda21dde671ac2e424e85bd270efafa719d4cb4">swh:1:rev:bdda21dde671ac2e424e85bd270efafa719d4cb4</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:ba259d42b72b464259463236c4d69d7fdaba5d6f;origin=https://github.com/pmeysman/HepBTCR;visit=swh:1:snp:9af24b74d71fc0603e410d162ef528d4e4a2a6ff;anchor=swh:1:rev:bdda21dde671ac2e424e85bd270efafa719d4cb4">https://archive.softwareheritage.org/swh:1:dir:ba259d42b72b464259463236c4d69d7fdaba5d6f;origin=https://github.com/pmeysman/HepBTCR;visit=swh:1:snp:9af24b74d71fc0603e410d162ef528d4e4a2a6ff;anchor=swh:1:rev:bdda21dde671ac2e424e85bd270efafa719d4cb4</ext-link></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittler</surname><given-names>RS</given-names></name><name><surname>Bailey</surname><given-names>TS</given-names></name><name><surname>Klussman</surname><given-names>K</given-names></name><name><surname>Trailsmith</surname><given-names>MD</given-names></name><name><surname>Hoffmann</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy</article-title><source>The Journal of Experimental Medicine</source><volume>190</volume><fpage>1535</fpage><lpage>1540</lpage><pub-id pub-id-type="doi">10.1084/jem.190.10.1535</pub-id><pub-id pub-id-type="pmid">10562327</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyara</surname><given-names>M</given-names></name><name><surname>Yoshioka</surname><given-names>Y</given-names></name><name><surname>Kitoh</surname><given-names>A</given-names></name><name><surname>Shima</surname><given-names>T</given-names></name><name><surname>Wing</surname><given-names>K</given-names></name><name><surname>Niwa</surname><given-names>A</given-names></name><name><surname>Parizot</surname><given-names>C</given-names></name><name><surname>Taflin</surname><given-names>C</given-names></name><name><surname>Heike</surname><given-names>T</given-names></name><name><surname>Valeyre</surname><given-names>D</given-names></name><name><surname>Mathian</surname><given-names>A</given-names></name><name><surname>Nakahata</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>Amoura</surname><given-names>Z</given-names></name><name><surname>Gorochov</surname><given-names>G</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Functional delineation and differentiation dynamics of human CD4T cells expressing the FoxP3 transcription factor</article-title><source>Immunity</source><volume>30</volume><fpage>899</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.03.019</pub-id><pub-id pub-id-type="pmid">19464196</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohr</surname><given-names>A</given-names></name><name><surname>Malhotra</surname><given-names>R</given-names></name><name><surname>Mayer</surname><given-names>G</given-names></name><name><surname>Gorochov</surname><given-names>G</given-names></name><name><surname>Miyara</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Human FOXP3+ T regulatory cell heterogeneity</article-title><source>Clin. Transl. Immunol</source><volume>7</volume><elocation-id>e1005</elocation-id><pub-id pub-id-type="doi">10.1002/cti2.1005</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pogorelyy</surname><given-names>MV</given-names></name><name><surname>Minervina</surname><given-names>AA</given-names></name><name><surname>Touzel</surname><given-names>MP</given-names></name><name><surname>Sycheva</surname><given-names>AL</given-names></name><name><surname>Komech</surname><given-names>EA</given-names></name><name><surname>Kovalenko</surname><given-names>EI</given-names></name><name><surname>Karganova</surname><given-names>GG</given-names></name><name><surname>Egorov</surname><given-names>ES</given-names></name><name><surname>Komkov</surname><given-names>AY</given-names></name><name><surname>Chudakov</surname><given-names>DM</given-names></name><name><surname>Mamedov</surname><given-names>IZ</given-names></name><name><surname>Mora</surname><given-names>T</given-names></name><name><surname>Walczak</surname><given-names>AM</given-names></name><name><surname>Lebedev</surname><given-names>YB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Precise tracking of vaccine-responding T cell clones reveals convergent and personalized response in identical twins</article-title><source>PNAS</source><volume>115</volume><fpage>12704</fpage><lpage>12709</lpage><pub-id pub-id-type="doi">10.1073/pnas.1809642115</pub-id><pub-id pub-id-type="pmid">30459272</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Precopio</surname><given-names>ML</given-names></name><name><surname>Butterfield</surname><given-names>TR</given-names></name><name><surname>Casazza</surname><given-names>JP</given-names></name><name><surname>Little</surname><given-names>SJ</given-names></name><name><surname>Richman</surname><given-names>DD</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Optimizing peptide matrices for identifying T-cell antigens</article-title><source>Cytometry. Part A</source><volume>73</volume><fpage>1071</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1002/cyto.a.20646</pub-id><pub-id pub-id-type="pmid">18781655</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reece</surname><given-names>WHH</given-names></name><name><surname>Pinder</surname><given-names>M</given-names></name><name><surname>Gothard</surname><given-names>PK</given-names></name><name><surname>Milligan</surname><given-names>P</given-names></name><name><surname>Bojang</surname><given-names>K</given-names></name><name><surname>Doherty</surname><given-names>T</given-names></name><name><surname>Plebanski</surname><given-names>M</given-names></name><name><surname>Akinwunmi</surname><given-names>P</given-names></name><name><surname>Everaere</surname><given-names>S</given-names></name><name><surname>Watkins</surname><given-names>KR</given-names></name><name><surname>Voss</surname><given-names>G</given-names></name><name><surname>Tornieporth</surname><given-names>N</given-names></name><name><surname>Alloueche</surname><given-names>A</given-names></name><name><surname>Greenwood</surname><given-names>BM</given-names></name><name><surname>Kester</surname><given-names>KE</given-names></name><name><surname>McAdam</surname><given-names>KPWJ</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Hill</surname><given-names>AVS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural <italic>Plasmodium falciparum</italic> infection and disease</article-title><source>Nature Medicine</source><volume>10</volume><fpage>406</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1038/nm1009</pub-id><pub-id pub-id-type="pmid">15034567</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reese</surname><given-names>TA</given-names></name><name><surname>Bi</surname><given-names>K</given-names></name><name><surname>Kambal</surname><given-names>A</given-names></name><name><surname>Filali-Mouhim</surname><given-names>A</given-names></name><name><surname>Beura</surname><given-names>LK</given-names></name><name><surname>Bürger</surname><given-names>MC</given-names></name><name><surname>Pulendran</surname><given-names>B</given-names></name><name><surname>Sekaly</surname><given-names>R-P</given-names></name><name><surname>Jameson</surname><given-names>SC</given-names></name><name><surname>Masopust</surname><given-names>D</given-names></name><name><surname>Haining</surname><given-names>WN</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Sequential Infection with Common Pathogens Promotes Human-like Immune Gene Expression and Altered Vaccine Response</article-title><source>Cell Host &amp; Microbe</source><volume>19</volume><fpage>713</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.04.003</pub-id><pub-id pub-id-type="pmid">27107939</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>AJ</given-names></name><name><surname>Campion</surname><given-names>SL</given-names></name><name><surname>Kopycinski</surname><given-names>J</given-names></name><name><surname>Moodie</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>ZM</given-names></name><name><surname>Pandya</surname><given-names>K</given-names></name><name><surname>Moore</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>MKP</given-names></name><name><surname>Brackenridge</surname><given-names>S</given-names></name><name><surname>Kuldanek</surname><given-names>K</given-names></name><name><surname>Legg</surname><given-names>K</given-names></name><name><surname>Cohen</surname><given-names>MS</given-names></name><name><surname>Delwart</surname><given-names>EL</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Fidler</surname><given-names>S</given-names></name><name><surname>McMichael</surname><given-names>AJ</given-names></name><name><surname>Goonetilleke</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals</article-title><source>Journal of Virology</source><volume>85</volume><fpage>3507</fpage><lpage>3516</lpage><pub-id pub-id-type="doi">10.1128/JVI.02444-10</pub-id><pub-id pub-id-type="pmid">21270166</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>CM</given-names></name><name><surname>Pfeiffer</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Viruses and the Microbiota</article-title><source>Annual Review of Virology</source><volume>1</volume><fpage>55</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-031413-085550</pub-id><pub-id pub-id-type="pmid">25821837</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Regulatory T cells and Foxp3</article-title><source>Immunological Reviews</source><volume>241</volume><fpage>260</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2011.01018.x</pub-id><pub-id pub-id-type="pmid">21488902</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudolph</surname><given-names>MG</given-names></name><name><surname>Stanfield</surname><given-names>RL</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>How TCRs bind MHCs, peptides, and coreceptors</article-title><source>Annual Review of Immunology</source><volume>24</volume><fpage>419</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.23.021704.115658</pub-id><pub-id pub-id-type="pmid">16551255</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Araki</surname><given-names>K</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>From vaccines to memory and back</article-title><source>Immunity</source><volume>33</volume><fpage>451</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.008</pub-id><pub-id pub-id-type="pmid">21029957</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>AM</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The development and function of memory regulatory T cells after acute viral infections</article-title><source>Journal of Immunology</source><volume>189</volume><fpage>2805</fpage><lpage>2814</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1200645</pub-id><pub-id pub-id-type="pmid">22855712</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenbrunn</surname><given-names>A</given-names></name><name><surname>Frentsch</surname><given-names>M</given-names></name><name><surname>Kohler</surname><given-names>S</given-names></name><name><surname>Keye</surname><given-names>J</given-names></name><name><surname>Dooms</surname><given-names>H</given-names></name><name><surname>Moewes</surname><given-names>B</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Loddenkemper</surname><given-names>C</given-names></name><name><surname>Sieper</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Romagnani</surname><given-names>C</given-names></name><name><surname>Matzmohr</surname><given-names>N</given-names></name><name><surname>Thiel</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3+ Treg</article-title><source>Journal of Immunology</source><volume>189</volume><fpage>5985</fpage><lpage>5994</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1201090</pub-id><pub-id pub-id-type="pmid">23162126</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seddiki</surname><given-names>N</given-names></name><name><surname>Santner-Nanan</surname><given-names>B</given-names></name><name><surname>Martinson</surname><given-names>J</given-names></name><name><surname>Zaunders</surname><given-names>J</given-names></name><name><surname>Sasson</surname><given-names>S</given-names></name><name><surname>Landay</surname><given-names>A</given-names></name><name><surname>Solomon</surname><given-names>M</given-names></name><name><surname>Selby</surname><given-names>W</given-names></name><name><surname>Alexander</surname><given-names>SI</given-names></name><name><surname>Nanan</surname><given-names>R</given-names></name><name><surname>Kelleher</surname><given-names>A</given-names></name><name><surname>Fazekas de St Groth</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells</article-title><source>The Journal of Experimental Medicine</source><volume>203</volume><fpage>1693</fpage><lpage>1700</lpage><pub-id pub-id-type="doi">10.1084/jem.20060468</pub-id><pub-id pub-id-type="pmid">16818676</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sewell</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Why must T cells be cross-reactive?</article-title><source>Nature Reviews. Immunology</source><volume>12</volume><fpage>669</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1038/nri3279</pub-id><pub-id pub-id-type="pmid">22918468</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shouval</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Hepatitis B vaccines</article-title><source>Journal of Hepatology</source><volume>39</volume><fpage>S70</fpage><lpage>S76</lpage><pub-id pub-id-type="doi">10.1016/s0168-8278(03)00152-1</pub-id><pub-id pub-id-type="pmid">14708681</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>LF</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Antiviral memory phenotype T cells in unexposed adults</article-title><source>Immunological Reviews</source><volume>255</volume><fpage>95</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1111/imr.12095</pub-id><pub-id pub-id-type="pmid">23947350</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>LF</given-names></name><name><surname>Kidd</surname><given-names>BA</given-names></name><name><surname>Han</surname><given-names>A</given-names></name><name><surname>Kotzin</surname><given-names>JJ</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Virus-Specific CD4+ Memory-Phenotype T Cells Are Abundant in Unexposed Adults</article-title><source>Immunity</source><volume>38</volume><fpage>373</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.10.021</pub-id><pub-id pub-id-type="pmid">23395677</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>SJ</given-names></name><name><surname>La Gruta</surname><given-names>NL</given-names></name><name><surname>Kedzierska</surname><given-names>K</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name><name><surname>Doherty</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Functional implications of T cell receptor diversity</article-title><source>Current Opinion in Immunology</source><volume>21</volume><fpage>286</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2009.05.004</pub-id><pub-id pub-id-type="pmid">19524428</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valkiers</surname><given-names>S</given-names></name><name><surname>Van Houcke</surname><given-names>M</given-names></name><name><surname>Laukens</surname><given-names>K</given-names></name><name><surname>Meysman</surname><given-names>P</given-names></name><name><surname>Boeva</surname><given-names>DV</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>ClusTCR: a python interface for rapid clustering of large sets of CDR3 sequences with unknown antigen specificity</article-title><source>Bioinformatics</source><volume>37</volume><fpage>4865</fpage><lpage>4867</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btab446</pub-id><pub-id pub-id-type="pmid">34132766</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><chapter-title>Modelling for Visualisation</chapter-title><source>Ggplot2</source><publisher-loc>Cham</publisher-loc><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/978-3-319-24277-4</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>DB</given-names></name><name><surname>Wilson</surname><given-names>DH</given-names></name><name><surname>Schroder</surname><given-names>K</given-names></name><name><surname>Pinilla</surname><given-names>C</given-names></name><name><surname>Blondelle</surname><given-names>S</given-names></name><name><surname>Houghten</surname><given-names>RA</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Specificity and degeneracy of T cells</article-title><source>Molecular Immunology</source><volume>40</volume><fpage>1047</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2003.11.022</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wing</surname><given-names>JB</given-names></name><name><surname>Ise</surname><given-names>W</given-names></name><name><surname>Kurosaki</surname><given-names>T</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Regulatory T Cells Control Antigen-Specific Expansion of Tfh Cell Number and Humoral Immune Responses via the Coreceptor CTLA-4</article-title><source>Immunity</source><volume>41</volume><fpage>1013</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.12.006</pub-id><pub-id pub-id-type="pmid">25526312</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>ES</given-names></name><name><surname>Thackray</surname><given-names>LB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A long-distance relationship: the commensal gut microbiota and systemic viruses</article-title><source>Current Opinion in Virology</source><volume>37</volume><fpage>44</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2019.05.009</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CD4+ T Cells Play a Critical Role in Microbiota-Maintained Anti-HBV Immunity in a Mouse Model</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>e927</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00927</pub-id><pub-id pub-id-type="pmid">31114580</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuen</surname><given-names>MF</given-names></name><name><surname>Chen</surname><given-names>DS</given-names></name><name><surname>Dusheiko</surname><given-names>GM</given-names></name><name><surname>Janssen</surname><given-names>HLA</given-names></name><name><surname>Lau</surname><given-names>DTY</given-names></name><name><surname>Locarnini</surname><given-names>SA</given-names></name><name><surname>Peters</surname><given-names>MG</given-names></name><name><surname>Lai</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hepatitis B virus infection</article-title><source>Nature Reviews Disease Primers</source><volume>4</volume><elocation-id>18035</elocation-id><pub-id pub-id-type="doi">10.1038/nrdp.2018.35</pub-id><pub-id pub-id-type="pmid">29877316</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells</article-title><source>Journal of Immunology</source><volume>173</volume><fpage>2428</fpage><lpage>2434</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.173.4.2428</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68388.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nourmohammad</surname><given-names>Armita</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Washington</institution><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2020.08.22.262568" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2020.08.22.262568"/></front-stub><body><p>By using modern high-throughput sequencing this paper demonstrates that the antibody mediated immune responses that are elicited by vaccination are improved by pre-existing memory CD4 T cell responses. The experimental data are an important contribution and would be useful as a data resource for future research. All reviewers agree that the findings are of great interest to the community.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68388.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Nourmohammad</surname><given-names>Armita</given-names></name><role>Reviewing Editor</role><aff><institution>University of Washington</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>de Boer</surname><given-names>Rob J</given-names></name><role>Reviewer</role><aff><institution>Utrecht University</institution><country>Netherlands</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>DeWitt</surname><given-names>William S</given-names></name><role>Reviewer</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2020.08.22.262568">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.08.22.262568v2">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon hepatitis B vaccination&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Aleksandra Walczak as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Rob J de Boer (Reviewer #2); William S DeWitt III (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Improve the statistical analysis for comparing the early- and late-converters: The authors compare Shannon entropy for day 60 vs. 0 and claim that the difference is more significant in early converters. The p-value however is marginal and does not support such strong claim, especially after taking into account multiple test correction. Please improve this analysis.</p><p>2) Develop a randomization test and a null model to show that the expansion of Ag specific T cells from day 0 to 60 is indeed significant.</p><p>3) Discuss how the commonality or differences in HLA types may impact the conclusions of the paper.</p><p>4) Since you cross validation is done for the ROC curves, please add error bars to the plots as well.</p><p>5) Better clarify the procedure for R<sub>hbs</sub> measure. What is the distance d? How is the distance cutoff parameter for epitope based classification is chosen? What are the statistics of bystander and non-bystander sequences? How robust are the results to this exact choice?</p><p>Ideally the authors should try more suitable TCR distance models like TCRdist by Dash et al. for this analysis.</p><p>6) Clarify the language throughout the manuscript as detailed by reviewer #2.</p><p>7) Better clarify the mathematical notations in the manuscript.</p><p>8) Improve the code in GitHub.</p><p>9) Improve the quality and resolution of the figures.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. Please make images properly in pdf – one can't zoom in and sometimes axis labels are unreadable.</p><p>2. Since you are doing cross validation in the ROC curves, please add error bars to the plots as well.</p><p>3. Figure 5a: I guess you tried to look for significant difference for all possible cell subsets. Have you corrected the p-value for multiple testing?</p><p>4. Given that the a central result of the paper derives from the ratio R<sub>hbs</sub> measure, more care must be given to properly explain what you are doing:</p><p>5. What is the distance d?</p><p>6. How do you set the free parameter c?</p><p>7. How many bystander and non-bystander sequences you have?</p><p>8. What do you get without the bystander normalisation (only numerator)?</p><p>9. Could you explain in more detail how do you select these bystander sequences?</p><p>10. Is this bystander normalisation already enough to classify early vs late converters or do you get also information from the numerator?</p><p>11. line162: can we understand this from the fact that late converters haven't yet built a proper response at day 60?</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The manuscript is not well written and most of the readers will not easily understand what exactly has been done in the various analysis. Most of my review will therefore asking for clarification.</p><p>Generally the language is not very exact. A few examples from page 4:</p><p>&quot;Antigen presentation via major histocompatibility complex (MHC) (encoded by HLA genes), together with the right costimulatory and cytokine signals, are responsible for T cell activation (Curtsinger and Mescher, 2010; Esensten et al., 2016).&quot;</p><p>– I miss the word proteins after (MHC).</p><p>On line 90 you write &quot;the highly degenerate nature of the CD4 T cell recognition&quot; and above you wrote that specificity is imparted.</p><p>Line 142: we detected a significant increase in the TCR repertoire Shannon's entropy for early-converters (Figure 2a): this looks like a very minor difference in Figure 2a. Which test was performed and what is the effect size?</p><p>Line 143: please explain what you mean by &quot;less clonal&quot;.</p><p>Line 153: measuring CFSE on day 60 and tracking clones from time point 0 to 60 probably means that you search for the clones that dilute CFSE on day 60 in the day 0 repertoires. This is not explained.</p><p>Line 156. &quot;a significant increase in the frequency of unique HBsAg-specific TCR sequences&quot;: what is the frequency of a unique sequence? Its abundance? Why then the &quot;unique&quot;? Do you mean &quot;a significant increase in the abundance of TCR sequences specific for HBsAg peptides&quot;?</p><p>Line 167: &quot;Thus, although we see a rise in the number of vaccine-specific TCR clonotypes from day 0 to day 60, this cannot be attributed to an expansion of preexisting TCR clonotypes but rather the recruitment of new TCR clonotypes&quot; I don't see how the number of vaccine-specific TCR clonotypes could have increased by an expansion of preexisting TCR clonotypes.</p><p>Line 169: &quot;rather the recruitment of new TCRB clonotypes (presumably from the naïve T cell compartment): how about memory clonotypes that were not present in the day 0 sample?</p><p>Line 200: Unclear sentence: &quot;These classifications were integrated into a model which outputs a ratio Rhbs for any TCR repertoire representing the amount of HBsAg peptide-specific clonotypes&quot;. Is the ratio Rhbs predicting the fraction of HBsAg peptide-specific clonotypes in a repertoire? Note that ratio, amount and fraction would then have the same meaning.</p><p>Line 200-215 is poorly written, e.g.,</p><p>– This model applied to the memory repertoire at day 60 shows.</p><p>– To account for the age variable, a model in which.….</p><p>Line 234-237 Hard to read sentence.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>There are some mathematical notation issues that make it difficult to understand the discriminative ratio R, as defined on line 591 in the methods. The function d(.,.) was previously defined as a hamming distance between sequences, but in this definition it takes arguments t<sub>repi</sub> and t<sub>pep</sub>, each of which is defined as a set of sequences. My interpretation is that {t<sub>repi</sub> | d(t<sub>repi</sub>, t<sub>pep</sub>) &lt; c} means something more like {x ∈ t<sub>repi</sub> | min_(y ∈ t<sub>pep</sub>) d(x, y) &lt; c}.</p><p>The code on GitHub needs substantial improvements to documentation. I was unable to find the part of the code where the c parameter is set for R<sub>hbs</sub>, or where the epitope specific clones are held out for the individual being classified in the LOO procedure. I suggest expanding the readme to detail how to use each script, perhaps with example commands, and where various important methodological details are implemented.</p><p>Many figure panels are of such low resolution that axis labels and annotations are illegible.</p><p>I would expect that HLA type would strongly influence the inter-individual relevance of the peptide specific TCRs, and the performance of this classifier (especially between individuals with different genetic backgrounds). Can the authors comment on why this wasn't an issue in this study?</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your article &quot;Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon hepatitis B vaccination&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Aleksandra Walczak as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Giulio Isacchini (Reviewer #1); Rob J de Boer (Reviewer #2); William S DeWitt III (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>By using modern high-throughput sequencing this paper demonstrates the antibody mediated immune responses that are elicited by vaccination are improved by pre-existing memory CD4 T cell responses. The experimental data are an important contribution and would be useful as a data resource for future research. All reviewers agree that the findings are great interest and the revision has addressed all the previous concerns.</p><p>Essential revisions:</p><p>1) Figure 1—figure supplement 1: early converters subfigure. Comparison between 180 and 365 does not look significant. Is the **** indication in the figure a mistake?</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The revised manuscript has considerably improved in quality and is ready for publication. The authors have clearly responded to the observations raised by the reviewers. The paper describes an original and important study and is of interest for <italic>eLife</italic> readers.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>I have read the rebuttal letter and find that the authors have responded well to my suggestions.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>The authors' responses to my comments on their initial submission are very thorough, and all of my concerns have been adequately addressed. They have improved the rigor of several statistical analyses, and clarified presentation of technical aspects that had previously been vague or confusing. They have also improved the open source code repository, adding more clear documentation of where key methods from the paper are implemented.</p><p>The findings of the manuscript are convincing, and the data is a valuable resource. I have no further concerns.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68388.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Improve the statistical analysis for comparing the early- and late-converters: The authors compare Shannon entropy for day 60 vs. 0 and claim that the difference is more significant in early converters. The p-value however is marginal and does not support such strong claim, especially after taking into account multiple test correction. Please improve this analysis.</p></disp-quote><p>This analysis has been removed and replaced with a more robust analysis based on the null model that has been added (see point #2).</p><disp-quote content-type="editor-comment"><p>2) Develop a randomization test and a null model to show that the expansion of Ag specific T cells from day 0 to 60 is indeed significant.</p></disp-quote><p>A null model has been added based on additional experimental data derived from VZV-specific T cells, which show no increase between day 0 and day 60.</p><disp-quote content-type="editor-comment"><p>3) Discuss how the commonality or differences in HLA types may impact the conclusions of the paper.</p></disp-quote><p>A section on the impact of HLA types has been added to the discussion.</p><disp-quote content-type="editor-comment"><p>4) Since you cross validation is done for the ROC curves, please add error bars to the plots as well.</p></disp-quote><p>Error bars have been added to the ROC curve where they remain visually distinct.</p><disp-quote content-type="editor-comment"><p>5) Better clarify the procedure for R<sub>hbs</sub> measure. What is the distance d? How is the distance cutoff parameter for epitope based classification is chosen? What are the statistics of bystander and non-bystander sequences? How robust are the results to this exact choice?</p></disp-quote><p>The explanation with regards to the Rhbs metric has been reworked in the revised manuscript based on the comments and suggestions.</p><disp-quote content-type="editor-comment"><p>Ideally the authors should try more suitable TCR distance models like TCRdist by Dash et al. for this analysis.</p></disp-quote><p>We have clarified our choice of distance model and referred to relevant literature.</p><disp-quote content-type="editor-comment"><p>6) Clarify the language throughout the manuscript as detailed by reviewer #2.</p></disp-quote><p>The reviewer suggestions with regards to language usage have been addressed. The manuscript has been carefully reread and any additional problems are hopefully now resolved.</p><disp-quote content-type="editor-comment"><p>7) Better clarify the mathematical notations in the manuscript.</p></disp-quote><p>The mathematical notation has been updated based on the reviewer comment.</p><disp-quote content-type="editor-comment"><p>8) Improve the code in GitHub.</p></disp-quote><p>The code base on GitHub has been substantially reworked. It now features a step-by-step help file and the script have been documented to refer to the manuscript definitions where possible.</p><disp-quote content-type="editor-comment"><p>9) Improve the quality and resolution of the figures.</p></disp-quote><p>The low quality of the figures is due to the conversion of the word document to PDF format. We will upload the source figure files separately in the submission of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. Please make images properly in pdf one can't zoom in and sometimes axis labels are unreadable.</p></disp-quote><p>We apologize for this inconvenience. The low quality of the figures is due to the conversion of the word document to PDF format by the manuscript handling system. We will upload the source figure files separately in the submission of the revised manuscript in the hopes that this will result in higher quality images.</p><disp-quote content-type="editor-comment"><p>2. Since you are doing cross validation in the ROC curves, please add error bars to the plots as well.</p></disp-quote><p>We have added a confidence interval to the ROC curves. However, we refrained from doing so for 4e and 4f as they feature three ROC curves simultaneously and comprehension becomes difficult with the confidence intervals.</p><disp-quote content-type="editor-comment"><p>3. Figure 5a: I guess you tried to look for significant difference for all possible cell subsets. Have you corrected the p-value for multiple testing?</p></disp-quote><p>Multiple testing correction is implemented throughout the manuscript. This has now been clarified in the manuscript text.</p><disp-quote content-type="editor-comment"><p>4. Given that the a central result of the paper derives from the ratio R<sub>hbs</sub> measure, more care must be given to properly explain what you are doing:</p></disp-quote><p>Several sections detailing the ratio R<sub>hbs</sub> measure have been clarified.</p><disp-quote content-type="editor-comment"><p>5. What is the distance d?</p></disp-quote><p>The distance d is defined as the Hamming distance between TCR CDR3 amino acid sequences. This has been clarified in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>6. How do you set the free parameter c?</p></disp-quote><p>We derive c from Meysman et al. (2018, Bioinformatics), where a value of 1 was found to be the most optimal threshold on a validation data set. This has been clarified in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>7. How many bystander and non-bystander sequences you have?</p></disp-quote><p>This is visualized in figure 3B which list the numerator and denominator values for each sample in the data set. This fact has been clarified in the caption.</p><disp-quote content-type="editor-comment"><p>8. What do you get without the bystander normalisation (only numerator)?</p></disp-quote><p>This can be inferred from figure 3B. The numerator alone provides a clear separation but is clearly inflated by the false positives. This has been clarified in the results and figure legend.</p><disp-quote content-type="editor-comment"><p>9. Could you explain in more detail how do you select these bystander sequences?</p></disp-quote><p>The relevant methods and Results section has been extended.</p><disp-quote content-type="editor-comment"><p>10. Is this bystander normalisation already enough to classify early vs late converters or do you get also information from the numerator?</p></disp-quote><p>See previous answer, the numerator provides most of the information with respect to the early converters. This has been clarified in the result text.</p><disp-quote content-type="editor-comment"><p>11. line162: can we understand this from the fact that late converters haven't yet built a proper response at day 60?</p></disp-quote><p>Indeed, at this time point, the late converters have not established a proper measurable T-cell response/antibody titer.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>The manuscript is not well written and most of the readers will not easily understand what exactly has been done in the various analysis. Most of my review will therefore asking for clarification.</p><p>Generally the language is not very exact.</p></disp-quote><p>Thank you for bringing this to our attention. We have endeavored to clarify the language throughout the manuscript.</p><disp-quote content-type="editor-comment"><p>A few examples from page 4:</p><p>&quot;Antigen presentation via major histocompatibility complex (MHC) (encoded by HLA genes), together with the right costimulatory and cytokine signals, are responsible for T cell activation (Curtsinger and Mescher, 2010; Esensten et al., 2016).&quot;</p><p>– I miss the word proteins after (MHC).</p></disp-quote><p>The word “protein” has been added.</p><disp-quote content-type="editor-comment"><p>On line 90 you write &quot;the highly degenerate nature of the CD4 T cell recognition&quot; and above you wrote that specificity is imparted.</p></disp-quote><p>These two sentences have now been corrected. They now read:</p><p>“The T-cell receptor (TCR) αβ heterodimer binds the peptide-MHC (pMHC) complex and confers the specificity of a T-cell to an epitope.”</p><p>“… as the encounter with environmentally-derived peptides activates cross-reactive T cells due to the flexible nature of the CD4 T-cell recognition of peptide-MHC complex.”</p><disp-quote content-type="editor-comment"><p>Line 142: we detected a significant increase in the TCR repertoire Shannon's entropy for early-converters (Figure 2a): this looks like a very minor difference in Figure 2a. Which test was performed and what is the effect size?</p></disp-quote><p>This section has been adapted with regards to the Shannon equitability index. In short, the prior findings were not robust to this change in definition. This is in line with what the reviewer indicates were a ‘very minor difference’. As they had no impact on the conclusions of the paper, they have been removed.</p><disp-quote content-type="editor-comment"><p>Line 143: please explain what you mean by &quot;less clonal&quot;.</p></disp-quote><p>This has been clarified to mean that a set of clonotypes have likely expanded in relative frequency.</p><disp-quote content-type="editor-comment"><p>Line 153: measuring CFSE on day 60 and tracking clones from time point 0 to 60 probably means that you search for the clones that dilute CFSE on day 60 in the day 0 repertoires. This is not explained.</p></disp-quote><p>We agree with the reviewer that this was unclear in the original manuscript. This point has been clearly explained in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Line 156. &quot;a significant increase in the frequency of unique HBsAg-specific TCR sequences&quot;: what is the frequency of a unique sequence? Its abundance? Why then the &quot;unique&quot;? Do you mean &quot;a significant increase in the abundance of TCR sequences specific for HBsAg peptides&quot;?</p></disp-quote><p>The term “increase in frequency of unique sequences” was an amalgam of terms, and has been replaced with the “increase in breadth”.</p><disp-quote content-type="editor-comment"><p>Line 167: &quot;Thus, although we see a rise in the number of vaccine-specific TCR clonotypes from day 0 to day 60, this cannot be attributed to an expansion of preexisting TCR clonotypes but rather the recruitment of new TCR clonotypes&quot; I don't see how the number of vaccine-specific TCR clonotypes could have increased by an expansion of preexisting TCR clonotypes.</p></disp-quote><p>This was indeed incorrectly worded and has been corrected.</p><disp-quote content-type="editor-comment"><p>Line 169: &quot;rather the recruitment of new TCRB clonotypes (presumably from the naïve T cell compartment): how about memory clonotypes that were not present in the day 0 sample?</p></disp-quote><p>This sentence has been rewritten to clarify that we indeed mean the contrast between the memory repertoires from day 0 and day 60. The postulated origin of these clonotypes has been removed to avoid unnecessary assumptions in the Results section.</p><disp-quote content-type="editor-comment"><p>Line 200: Unclear sentence: &quot;These classifications were integrated into a model which outputs a ratio Rhbs for any TCR repertoire representing the amount of HBsAg peptide-specific clonotypes&quot;. Is the ratio Rhbs predicting the fraction of HBsAg peptide-specific clonotypes in a repertoire? Note that ratio, amount and fraction would then have the same meaning.</p></disp-quote><p>This section now details a stricter definition to avoid confusion. We have also opted to use the term ‘breadth’ were appropriate to be specific which parameters are being used.</p><disp-quote content-type="editor-comment"><p>Line 200-215 is poorly written, e.g.,</p><p>– This model applied to the memory repertoire at day 60 shows.</p><p>– To account for the age variable, a model in which.….</p></disp-quote><p>This section has been substantially rewritten.</p><disp-quote content-type="editor-comment"><p>Line 234-237 Hard to read sentence.</p></disp-quote><p>The sentence has not been modified to make it clearer. CD25+CD127<sup>−</sup> and CD25<sup>−</sup>CD27+ phenotype can be used to identify T<sub>REG</sub> and T<sub>CON</sub> cells and in this case, we show that CD40L<sup>+</sup>4-1BB<sup>−</sup> and CD40L<sup>−</sup>4-1BB<sup>+</sup> CD4 T as captured by activation markers do agree with this classification and hence support the use of the converse expression of CD40L and 4-1BB as signature of the two CD4 T cell phenotypes.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>There are some mathematical notation issues that make it difficult to understand the discriminative ratio R, as defined on line 591 in the methods. The function d(.,.) was previously defined as a hamming distance between sequences, but in this definition it takes arguments t<sub>repi</sub> and t<sub>pep</sub>, each of which is defined as a set of sequences. My interpretation is that {t<sub>repi</sub> | d(t<sub>repi</sub>, t<sub>pep</sub>) &lt; c} means something more like {x ∈ t<sub>repi</sub> | min_(y ∈ t<sub>pep</sub>) d(x, y) &lt; c}.</p></disp-quote><p>The reviewer is correct is their interpretation of the discriminative ratio R. The suggested alterations to the formula have been implemented in the text.</p><disp-quote content-type="editor-comment"><p>The code on GitHub needs substantial improvements to documentation. I was unable to find the part of the code where the c parameter is set for R<sub>hbs</sub>, or where the epitope specific clones are held out for the individual being classified in the LOO procedure. I suggest expanding the readme to detail how to use each script, perhaps with example commands, and where various important methodological details are implemented.</p></disp-quote><p>We agree with the reviewer that the previous code base lacked proper documentation. We have now greatly extended this with a step-by-step guide and additional comments. In addition, we have rewritten the code to be more legible, while confirming that no results have been impacted. In particular, the R<sub>hbs</sub> parameters are now explicitly marked in the code where they are generated. At the reviewers request, the c parameter has been extracted from the inner workings of the hamming distance calculator to a parameter that is set at the start of the code (within peptide.py).</p><disp-quote content-type="editor-comment"><p>Many figure panels are of such low resolution that axis labels and annotations are illegible.</p></disp-quote><p>We apologize for this inconvenience. The low quality of the figures is due to the conversion of the word document to PDF format by the manuscript handling system. We will upload the source figure files separately in the submission of the revised manuscript in the hopes that this will result in higher quality images.</p><disp-quote content-type="editor-comment"><p>I would expect that HLA type would strongly influence the inter-individual relevance of the peptide specific TCRs, and the performance of this classifier (especially between individuals with different genetic backgrounds). Can the authors comment on why this wasn't an issue in this study?</p></disp-quote><p>This is an important point raised by the reviewer. We have added a comment on this fact to the discussion, it reads:</p><p>“This is a non-trivial task as the MHC class II molecules vary between vaccinees, which in turn allows for great variation of the presented epitopes. However, we were able to cover the entire HBsAg and obtained a sufficient sample size to likely cover the most immunoprevalent epitopes. It can be presumed that we do not capture the full HBsAg T cell response, but obtain enough sequences which are representative for the response as a whole.”</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Figure 1—figure supplement 1: early converters subfigure. Comparison between 180 and 365 does not look significant. Is the **** indication in the figure a mistake?</p></disp-quote><p>We revisited the script. The comparison of the antibody titer between day 180 and 365 for early-converters is significantly different and it is not a typo. This is a paired analysis and indeed, as shown in <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>, the decrease in antibody titer is consistent for all vaccinees between day 180 and day 365 while the increase between day 60 and day 180 is not.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68388-sa2-fig1-v3.tif"/></fig><table-wrap id="sa2table1" position="float"><label>Author response table 1.</label><table frame="hsides" rules="groups"><thead><tr><th>Median of antibody titer over time</th><th/><th/><th/><th/></tr></thead><tbody><tr><td align="left" valign="top">Status</td><td align="left" valign="top">Time_Point</td><td align="left" valign="top">Antibody_titre_median</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Early-converter</td><td align="left" valign="top">0</td><td align="left" valign="top">2</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Early-converter</td><td align="left" valign="top">60</td><td align="left" valign="top">82.23</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Early-converter</td><td align="left" valign="top">180</td><td align="left" valign="top">167.7</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Early-converter</td><td align="left" valign="top">365</td><td align="left" valign="top">62.01</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Statistical analysis</td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">group1</td><td align="left" valign="top">group2</td><td align="left" valign="top">p</td><td align="left" valign="top">p.adj</td><td align="left" valign="top">p.adj.signif</td></tr><tr><td align="left" valign="top">0</td><td align="left" valign="top">60</td><td align="left" valign="top">9.54E-07</td><td align="left" valign="top">4.77E-06</td><td align="left" valign="top">****</td></tr><tr><td align="left" valign="top">60</td><td align="left" valign="top">180</td><td align="left" valign="top">0.785</td><td align="left" valign="top">1</td><td align="left" valign="top">ns</td></tr><tr><td align="left" valign="top">180</td><td align="left" valign="top">365</td><td align="left" valign="top">9.54E-07</td><td align="left" valign="top">4.77E-06</td><td align="left" valign="top">****</td></tr><tr><td align="left" valign="top">0</td><td align="left" valign="top">180</td><td align="left" valign="top">9.54E-07</td><td align="left" valign="top">4.77E-06</td><td align="left" valign="top">****</td></tr><tr><td align="left" valign="top">0</td><td align="left" valign="top">365</td><td align="left" valign="top">9.54E-07</td><td align="left" valign="top">4.77E-06</td><td align="left" valign="top">****</td></tr></tbody></table></table-wrap></body></sub-article></article>